[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 136
1. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G: Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol; 2010 Jul 10;28(20):3316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
  • PURPOSE: In malignant mesothelioma (MM), radiologic assessment of disease status is difficult.
  • Both soluble mesothelin-related peptide (SMRP) and osteopontin (OP) have utility in distinguishing MM from benign pleural disease.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Peritoneal Neoplasms / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. GPI-Linked Proteins. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20498407.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


2. Boldú J, Eguía VM: [Benign pleural diseases induced by asbestos]. An Sist Sanit Navar; 2005;28 Suppl 1:21-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign pleural diseases induced by asbestos].
  • Exposure to asbestos is an important cause of pleural pathology and can be produced with light or moderate tendencies given the capacity of asbestos to concentrate in the pleura.
  • Together with the prolonged latency existing between exposure and the disease, this means that for many years we will continue to see pleural clinical manifestations from past exposure, in spite of the increasingly limited use of asbestos in recent decades.
  • This exposure can show itself in different manifestations, both malign, such as mesothelioma, and benign, principally benign pleural effusion, pleural plaques, diffuse pleural fibrosis and massive atelectasis.
  • [MeSH-major] Asbestos / adverse effects. Fibrosis / epidemiology. Fibrosis / etiology. Pleural Diseases / epidemiology. Pleural Diseases / etiology. Pulmonary Atelectasis / epidemiology. Pulmonary Atelectasis / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915168.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


3. Stević R, Jovanović D, Mandarić M, Pesut D, Masulović D, Stosić-Opinćal T, Adzić T, Vasić N: [Radiologic manifestation of primary pleural tumors]. Acta Chir Iugosl; 2009;56(4):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiologic manifestation of primary pleural tumors].
  • OBJECTIVES: To show the radiological manifestations of primary pleural tumors.
  • PATIENTS AND METHODS: we carried out a retrospective analysis of radiological findings in 62 patients with primary malignant tumor of pleura.
  • Malignant tumors were present in 92.7% of the patients and benign ones in 7.2%.
  • The most common malignant tumor was mesothelioma (85.4%), and solitary fibrous tumor prevailed among benign tumors (9.7%).
  • Diffuse malignant mesothelioma manifested on computed tomography (CT) as a pleural thickening and effusion in 67.4% of the patients, tumors and effusion in 11.7%, and only as an effusion in 9.8% cases.
  • Thickening of the pleura appeared diffuse in 54% of patients and most often it had nodular pattern.
  • Both localized malignant and all benign tumors presented as tumor-like changes with the signs of necrosis in 50%.
  • CONCLUSION: The imaging methods have a key role in the diagnosis of pleural tumors.
  • CT shows different morphologic features of pleural lesions that have been established as a useful tool for differentiating malignant from benign disease.
  • However, magnetic resonance is preferred imaging method for assessing the extent and resectability of pleural tumors.
  • [MeSH-major] Pleural Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Mesothelioma / radiography. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419999.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


Advertisement
4. Gill RR, Umeoka S, Mamata H, Tilleman TR, Stanwell P, Woodhams R, Padera RF, Sugarbaker DJ, Hatabu H: Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol; 2010 Aug;195(2):W125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
  • OBJECTIVE: The purpose of this study was to prospectively assess, in the evaluation of patients with suspected malignant pleural mesothelioma (MPM), apparent diffusion coefficient (ADC) values derived from diffusion-weighted images obtained with a free-breathing single-shot spin-echo echo-planar imaging sequence and to correlate the ADC values with the three histologic subtypes of MPM.
  • SUBJECTS AND METHODS: Sixty-two patients with a known pleural abnormality and clinical findings suggestive of MPM underwent diffusion-weighted 3-T MRI and ADC calculation.
  • The pathologic diagnosis was confirmed by surgical procedure.
  • The other five patients had pleural thickening (two patients), metastatic adenocarcinoma (one patient), chronic inflammation (one patient), and malignant lymphoma (one patient).
  • The ADC in the two cases of benign plaque was 0.85 +/- 0.17 x 10(-3) mm(2)/s.
  • CONCLUSION: The ADC values of epithelioid mesothelioma are higher than those of sarcomatoid mesothelioma.
  • [MeSH-major] Algorithms. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Mesothelioma / classification. Mesothelioma / pathology. Pleural Neoplasms / classification. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651171.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • BACKGROUND: Immunohistochemistry is helpful in distinguishing metastatic carcinoma from atypical mesothelial cells; however, it is not useful in differentiating atypical mesothelial cells from malignant mesothelial cells.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • The associated reactive mesothelial cells were negative for KOC but positive for calretinin and CK5/6.
  • In addition, 16 cases that were originally diagnosed either as pleural effusions with reactive mesothelial cells (14) or atypical cells with uncertain significance (2) were also tested for KOC expression.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • CONCLUSIONS: Anti-L523S antibody is a useful marker for the detection of malignant cells in serous effusions and it can have significant utility in differentiating reactive mesothelial cells from malignant mesothelioma and metastatic carcinoma in combination with calretinin and CK5/6 staining.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


6. Steinert HC: PET in lung cancer. Chang Gung Med J; 2005 May;28(5):296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate tumor staging is essential for choosing the appropriate treatment strategy in patients with lung cancer.
  • It has already been shown that FDG-PET is highly accurate in classifying lung nodules as benign or malignant.
  • PET-CT is superior in diagnostic accuracy for T staging and differentiation between tumor and peritumoral atelectasis.
  • A very high accuracy of FDG-PET in distinguishing recurrent disease from benign treatment effects has been shown.
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Small Cell / radionuclide imaging. Fluorodeoxyglucose F18. Humans. Mesothelioma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging. Pleural Neoplasms / radionuclide imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086544.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 29
  •  go-up   go-down


7. Mahmood S, Martinez de Llano SR: Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT. Clin Nucl Med; 2008 Jul;33(7):510-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.
  • A 71-year-old man with newly diagnosed malignant mesothelioma was referred for an F-18 FDG PET/CT study to evaluate the extent of disease.
  • PET showed mild FDG uptake in the right chest, corresponding to a lobulated, mass-like right pleural effusion versus thickening involving the entire right pleural space, and some mediastinal involvement, on the accompanying CT scan.
  • The intense FDG uptake in an osseous lesion on FDG-PET in our case reminds us of the variable nature of FDG uptake in Paget disease, the possibility of false-positive findings on FDG-PET in patients with cancer, and the usefulness of the fusion techniques in the evaluation of skeletal lesions, with the potential for discriminating between benign Paget disease and other pathologic bone findings.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / radionuclide imaging. Humerus / radionuclide imaging. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Mesothelioma / diagnosis. Mesothelioma / radionuclide imaging. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / radionuclide imaging. Osteitis Deformans / diagnosis. Osteitis Deformans / radionuclide imaging
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18 / pharmacology. Humans. Male. Neoplasm Metastasis. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacology. Tomography, X-Ray Computed / methods


8. Davidson B, Dong HP, Holth A, Berner A, Risberg B: Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol; 2007 May;127(5):752-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
  • We studied chemokine receptor expression in malignant mesothelioma (MM), reactive mesothelium (RM), and leukocytes in effusions.
  • Chemokine receptors are widely expressed on leukocytes in MM and RM effusions but are infrequently found on cells of mesothelial origin.
  • The increased monocyte infiltration and their higher chemokine receptor expression in MM effusions may have a tumor-promoting rather than tumor-inhibiting effect.
  • [MeSH-major] Epithelial Cells / immunology. Leukocytes / immunology. Mesothelioma / immunology. Receptors, Chemokine / analysis
  • [MeSH-minor] Adenocarcinoma / immunology. Adult. Aged. Aged, 80 and over. Ascitic Fluid / immunology. Female. Humans. Male. Middle Aged. Pleural Effusion / immunology. Receptors, CXCR4 / analysis. Receptors, Interleukin-8A / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439834.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; 0 / Receptors, Interleukin-8A
  •  go-up   go-down


9. Plathow C, Schoebinger M, Herth F, Tuengerthal S, Meinzer HP, Kauczor HU: Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results. Korean J Radiol; 2009 Nov-Dec;10(6):559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a proof of concept, the technique was applied in five patients with non-small cell lung cancer (NSCLC) and 5 patients with malignant pleural mesothelioma (MPM).
  • The patients with NSCLC showed a local lack of lung motion in the area of the tumor.
  • In the patients with MPM, there was global diminished motion of the tumor bearing hemithorax, which improved significantly after chemotherapy (CHT) (assessed by the 2D- and 3D-techniques) (p < 0.01).
  • Local and global parenchymal pathologies can be precisely located and might be a new tool used to quantify even slight changes in lung motion (e.g. in therapy monitoring, follow-up studies or even benign lung diseases).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / physiopathology. Imaging, Three-Dimensional. Lung Neoplasms / physiopathology. Magnetic Resonance Imaging / methods. Mesothelioma / physiopathology. Movement / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):467-74 [11241824.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):631-5 [17685425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):335-41 [12738306.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):542-7 [14509953.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):968-78 [14575827.001]
  • [Cites] Acad Radiol. 2003 Oct;10(10):1147-52 [14587632.001]
  • [Cites] Invest Radiol. 2004 Apr;39(4):202-9 [15021323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):952-9 [15234028.001]
  • [Cites] Eur Radiol. 2004 Aug;14(8):1392-9 [15127220.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):335-41 [15337573.001]
  • [Cites] Am Rev Respir Dis. 1987 Oct;136(4):867-71 [3662240.001]
  • [Cites] Radiology. 1989 Jun;171(3):841-5 [2717762.001]
  • [Cites] Clin Chest Med. 1990 Sep;11(3):405-16 [2205439.001]
  • [Cites] J Magn Reson Imaging. 1999 Oct;10(4):510-20 [10508317.001]
  • [Cites] Radiother Oncol. 2004 Dec;73(3):349-54 [15588881.001]
  • [Cites] Invest Radiol. 2005 Jan;40(1):40-8 [15597019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):594-607 [15667982.001]
  • [Cites] Invest Radiol. 2005 Mar;40(3):173-9 [15714092.001]
  • [Cites] Med Image Anal. 2005 Dec;9(6):594-604 [15896995.001]
  • [Cites] Invest Radiol. 2006 May;41(5):443-8 [16625107.001]
  • [Cites] Radiology. 2006 Aug;240(2):537-45 [16801367.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1942-50 [16628438.001]
  • [Cites] Methods Inf Med. 2007;46(3):275-81 [17492112.001]
  • [Cites] Inf Process Med Imaging. 2007;20:1-12 [17633684.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):131-8 [12601277.001]
  • (PMID = 19885311.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2770821
  • [Keywords] NOTNLM ; Biomechanics / Dynamic MRI / Intraparenchymal lung motion / Pleural mesothelioma / Tumor
  •  go-up   go-down


10. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer; 2010 Apr;68(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
  • In effusion cytology, adjuvant techniques are often needed for the differentiation of reactive proliferating mesothelial cells and malignant cells.
  • In the case of malignancy the further challenge is to distinguish metastatic tumors from the primary malignant mesothelioma.
  • Moreover, it has been proposed that a homozygous deletion of the p16(INK4A) gene could more specifically identify malignant mesothelial cells among the exfoliated cells.
  • The first objective of this study was to adapt the commercial FISH-test, UroVysion originally designed for the cytological diagnosis of bladder cancer, to the analysis of cells in effusions.
  • Sixty-eight pleural effusions were evaluated.
  • The cytological diagnosis was malignant in 29 cases, inconclusive in 24 cases and benign in 15 cases.
  • The independently verified final diagnoses were mesothelioma in 21 cases, metastatic cancer in 29 and benign in 18 cases.
  • The algorithm for aneuploidy distinguished almost all tested malignant conditions from benign ones, also those with inconclusive cytology.
  • [MeSH-major] Breast Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Aneuploidy. Diagnosis, Differential. Female. Genes, p16. Humans. Pleural Effusion, Malignant / pathology. Reagent Kits, Diagnostic. Sequence Deletion / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19523712.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


11. Guinee DG, Allen TC: Primary pleural neoplasia: entities other than diffuse malignant mesothelioma. Arch Pathol Lab Med; 2008 Jul;132(7):1149-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pleural neoplasia: entities other than diffuse malignant mesothelioma.
  • CONTEXT: Overwhelmingly, the most common neoplasm involving the pleura is metastatic carcinoma.
  • In contrast, diffuse malignant mesothelioma occurs relatively rarely; however, it is nonetheless the most common neoplasm primary to the pleura.
  • Metastatic carcinoma and diffuse malignant mesothelioma each have their own prognostic and therapeutic characteristics.
  • Other primary pleural neoplasms occur uncommonly or rarely, with their own prognostic and therapeutic characteristics.
  • OBJECTIVE: To review primary pleural neoplasms other than diffuse malignant mesothelioma, to better ensure correct diagnosis and optimal assessment of prognosis and treatment.
  • CONCLUSIONS: A nonexhaustive group of uncommon to rare benign and malignant primary pleural neoplasms--other than diffuse malignant mesothelioma--are presented, of which one must be aware in order to maintain an appropriate index of suspicion to include them in the differential diagnosis of a pleural tumor.
  • [MeSH-major] Pleural Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18605768.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 244
  •  go-up   go-down


12. Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF: Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Med Clin (Barc); 2009 Oct 3;133(12):449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
  • BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases.
  • Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM.
  • PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had benign pleural effusion (8 infectious disease and 13 idiopathic effusion).
  • RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with benign effusion (P=0.02).
  • When malignant pleural effusions were analyzed separately, MM patients had the highest median pleural fluid SMRP concentration, with significant differences as compared to patients with idiopathic pleural effusion.
  • CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Hematologic Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Membrane Glycoproteins / analysis. Mesothelioma / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Male. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric


13. Addis B, Roche H: Problems in mesothelioma diagnosis. Histopathology; 2009 Jan;54(1):55-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Problems in mesothelioma diagnosis.
  • Many centres are now seeing increasing numbers of patients with malignant mesothelioma.
  • This presents pathologists involved in making the diagnosis with a number of problems, which can be divided into those encountered in making the distinction between mesothelioma and benign changes and those experienced in separating mesotheliomas from other types of epithelial and connective tissue tumours.
  • Immunohistochemistry plays a major role in helping to make the diagnosis, but it should be interpreted with due regard to the clinical setting and radiological features, and with a knowledge of the wide morphological variations seen in mesothelioma.
  • It includes a discussion of some of the less common variants of mesothelioma and other pleural-based tumours that enter into the differential diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054156.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 101
  •  go-up   go-down


14. Hansson M, Zendehrokh N, Ohyashiki J, Ohyashiki K, Westman UB, Roos G, Dejmek A: Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay. Arch Pathol Lab Med; 2008 Dec;132(12):1896-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: We previously found telomere repeat amplification protocol (TRAP) in situ helpful in the diagnosis of malignancy in effusions, whereas varying sensitivities and specificities for malignancy were reported by investigators using extract-based TRAP.
  • Five of 7 benign effusions were negative; in 2 of 7, mesothelial cells showed weak reactivity.
  • The relative telomerase activities were 33.1 to 72.7 with a considerable overlap between malignant (48 +/- 9, mean +/- SD) and benign (43 +/- 9) cases.
  • CONCLUSIONS: The TRAP in situ results correlated to final diagnoses, whereas the cell lysate-based TRAP assay did not differentiate between malignant and benign cases.
  • [MeSH-major] Ascitic Fluid / enzymology. Enzyme-Linked Immunosorbent Assay / methods. Nucleic Acid Amplification Techniques / methods. Pericardial Effusion / enzymology. Pleural Effusion, Malignant / enzymology. Telomerase / metabolism. Telomere / genetics
  • [MeSH-minor] Humans. Mesothelioma / diagnosis. Mesothelioma / enzymology. Mesothelioma / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / enzymology. Peritoneal Neoplasms / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / enzymology. Pleural Neoplasms / pathology. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061286.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


15. Kradin RL, Mark EJ: Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach. Semin Diagn Pathol; 2006 Feb;23(1):4-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.
  • This paper examines the spectrum of challenges that confront the diagnostic surgical pathologist in distinguishing benign mesothelial hyperplasia from malignant mesothelioma.
  • The current state of the art with respect to the morphological, immunohistological, and molecular features that can assist in the evaluation of benign and malignant pleural disease is examined.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / diagnosis. Pleura / pathology. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Hyperplasia. Immunohistochemistry. Pleural Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044190.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


16. Cagle PT, Churg A: Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med; 2005 Nov;129(11):1421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
  • CONTEXT: Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia.
  • DESIGN: Based on previous medical publications, extensive personal consultations, and experience on the United States-Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies.
  • RESULTS: Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult.
  • Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland.
  • Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion.
  • CONCLUSIONS: Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa.
  • Invasion is the most reliable criterion for determining that a mesothelial proliferation is malignant.
  • When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Hyperplasia / pathology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


17. Tagliabue F, Vertemati G, Confalonieri G, Romelli A, Terragni S, Costa M: Benign solitary fibrous tumour of the pleura: a clinical review and report of six cases. Chir Ital; 2005 Sep-Oct;57(5):649-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign solitary fibrous tumour of the pleura: a clinical review and report of six cases.
  • Primary tumours of the pleura are commonly divided into two major categories: diffuse and localised.
  • Electron microscopy and immunohistochemistry have recently demonstrated that these tumours are of mesenchymal rather than mesothelial origin, and therefore the term "localised mesothelioma" was abandoned.
  • Such tumours are now called solitary fibrous tumours of the pleura (SFTP).
  • The Authors describe a series of 6 cases of benign solitary fibrous tumours of the pleura, surgically treated over the period 1982-2000.
  • [MeSH-major] Neoplasms, Fibrous Tissue. Pleural Neoplasms
  • [MeSH-minor] Adult. Aged. Algorithms. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Microscopy, Electron. Middle Aged. Pleura / pathology. Radiography, Thoracic. Terminology as Topic. Thoracoscopy. Thoracotomy. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16241098.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Creaney J, Musk AW, Robinson BW: Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol; 2010 Sep;5(9):1461-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
  • INTRODUCTION: Malignant mesothelioma (MM) is an aggressive, uniformly fatal tumor usually caused by exposure to asbestos.
  • METHODS: Soluble mesothelin concentrations were determined using the MESOMARK assay in concurrent serum and urine samples from 70 patients with pleural MM, 111 patients with asbestos-related lung or pleural disease, and 45 patients with benign nonasbestos-related lung and pleural disease.
  • RESULTS: At a specificity of 95% relative to individuals with benign lung or pleural disease, serum mesothelin had a sensitivity of 66% and area under the curve of 0.882, whereas urinary mesothelin corrected for urine creatinine concentration had a sensitivity of 53% and area under the curve of 0.787.
  • CONCLUSIONS: The sensitivity of urinary mesothelin does not warrant the use of urine as a biomarker specimen for MM diagnosis.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / urine. Membrane Glycoproteins / urine. Mesothelioma / urine. Pleural Neoplasms / urine

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815094.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos; AYI8EX34EU / Creatinine
  •  go-up   go-down


19. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):646-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) results from malignant transformation of mesothelial cells.
  • Past asbestos exposure represents a major risk factor for MPM and other benign pleural disease.
  • The aim of this study was to investigate serum levels of SMRP in malignant and nonmalignant asbestos-related pleural disease.
  • PATIENTS: Four groups of patients were investigated: group 1 composed of 48 healthy subjects, group 2 composed of 177 patients with previous asbestos exposure and no pleural disease, group 3 composed of 36 patients with MPM, and group 4 composed of 101 patients with previous asbestos exposure and benign pleural disease.
  • Subjects exposed to asbestos had higher SMRP concentrations than normal control subjects regardless of the presence of pleural disease.
  • The SMRP level at 0.55 nmol/L/L was determined as the most optimal cutoff value with resulting sensitivity and specificity of 72% and 72% for the diagnosis of MPM.
  • CONCLUSIONS: These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190155.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


20. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y: Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol; 2007 Feb;20(2):215-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.
  • The separation of benign reactive mesothelium (RM) from malignant mesothelial proliferation can be a major challenge.
  • To date, however, no immunohistochemical marker that allows unequivocal discrimination of RM from malignant pleural mesothelioma (MPM) has been available.
  • GLUT-1 is largely undetectable by immunohistochemistry in normal epithelial tissues and benign tumors, but is expressed in a variety of malignancies.
  • Recently, in fact, some studies have shown that GLUT-1 expression is useful for distinguishing benign from malignant lesions.
  • GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of RM from MPM, whereas it cannot discriminate MPM from lung carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Glucose Transporter Type 1 / metabolism. Immunoenzyme Techniques. Mesothelioma / metabolism. Pleural Neoplasms / metabolism. Pleurisy / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Membrane / metabolism. Cell Membrane / pathology. Diagnosis, Differential. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192790.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1
  •  go-up   go-down


21. Baas P, Triesscheijn M, Burgers S, van Pel R, Stewart F, Aalders M: Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid. Chest; 2006 Mar;129(3):718-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid.
  • STUDY OBJECTIVE: Although the use of video-assisted thoracoscopy has improved the diagnostic accuracy in patients presenting with pleural diseases, not all biopsies performed are conclusive and staging of the disease is not always optimal.
  • Fluorescence diagnosis (FD) with 5-aminolaevulinic acid (5-ALA) has been used in the diagnostic workup for various malignancies.
  • The impact of 5-ALA-mediated FD on diagnosis and staging during video-assisted thoracoscopy was examined.
  • PATIENTS: Twenty-six patients with nonconclusive pleural effusions who were scheduled for video-assisted thoracoscopy.
  • After conventional inspection with white light, fluorescence inspection of the pleural cavity was performed (D-LIGHT Auto Fluorescent System; Karl Storz; Tuttlingen, Germany).
  • A definitive diagnosis was obtained in 24 of 25 cases, with malignant mesothelioma in 15 cases, other malignancies in 5 cases, one infection, and three benign diseases.
  • Upstaging occurred in four patients (unsuspected tumor deposits) due to FD examination.
  • CONCLUSIONS: FD using 5-ALA in the pleural cavity is feasible with limited side effects when used in addition to white light inspection.
  • It improved visualization of abnormal lesions and led to upstaging in 4 of 15 mesothelioma patients.
  • [MeSH-major] Aminolevulinic Acid. Photosensitizing Agents. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Male. Mesothelioma / diagnosis. Middle Aged. Prospective Studies. Thoracic Surgery, Video-Assisted. Thoracoscopy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537873.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


22. Terra Filho M, de Freitas JB, Nery LE: [Asbestos-related diseases]. J Bras Pneumol; 2006;32 Suppl 2:S48-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latest diagnostic, radiological, computed tomography and lung function aspects of benign pleural disease, asbestosis, occupational lung cancer and mesothelioma are discussed.
  • [MeSH-minor] Humans. Lung Neoplasms / etiology. Mesothelioma / etiology. Pleural Diseases / etiology. Tomography, X-Ray Computed. Tuberculosis, Pulmonary / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273598.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 29
  •  go-up   go-down


23. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med; 2009 Jul;15(4):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and pleural fluid biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Malignant mesothelioma is an asbestos-induced, aggressive tumour.
  • In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring.
  • With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field.
  • The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease.
  • The assay has a high level of specificity relative to benign lung and pleural conditions and is positive in 10-15% of other malignancies.
  • SUMMARY: To date, soluble mesothelin remains the best available biomarker for malignant mesothelioma.
  • However, a lack of sensitivity for early-stage disease and for all malignant mesothelioma histologies provides motivation for the search of novel malignant mesothelioma biomarkers with greater sensitivity, especially for very early disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis
  • [MeSH-minor] GPI-Linked Proteins. Humans. Membrane Glycoproteins / metabolism. Osteopontin / metabolism. Pleural Cavity / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417672.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  • [Number-of-references] 52
  •  go-up   go-down


24. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol; 2008 Aug;3(8):851-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
  • INTRODUCTION: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma.
  • Three potential markers for mesothelioma are mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin.
  • The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers.
  • METHODS: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies.
  • RESULTS: Serum levels of the three markers were elevated in mesothelioma patients.
  • At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin.
  • Osteopontin and MPF were unable to differentiate patients with mesothelioma from patients with other malignancies or those presenting with transudative pleural effusions.
  • Combining the data from the three biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone.
  • CONCLUSION: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670302.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


25. Rakovich G, Laflamme M, Ouellette D, Beauchamp G: Solitary fibrous tumour of the pleura: A case report. Can Respir J; 2010 May-Jun;17(3):113-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the pleura: A case report.
  • Solitary fibrous tumours of the pleura are rare pleural neoplasms that are distinct from mesothelioma.
  • Most of them are benign, although some behave aggressively; morphological and pathological features are important in distinguishing them from mesothelioma and in predicting clinical behaviour.
  • In cases of benign lesions, complete resection is usually curative.
  • A case involving a 62-year-old woman who underwent surgical resection of a solitary fibrous tumour of the pleura measuring 25 cm in size is described.
  • [MeSH-major] Pleura / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Imaging. 2005 May;20(2):118-9 [15818213.001]
  • [Cites] Chest. 2006 Aug;130(2):581-3 [16899864.001]
  • [Cites] World J Surg. 2008 Aug;32(8):1663-8 [18427887.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3154-60 [19451429.001]
  • (PMID = 20617210.001).
  • [ISSN] 1916-7245
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2900141
  •  go-up   go-down


26. Terry NE, Fowler CL: Benign cystic mesothelioma in a child. J Pediatr Surg; 2009 May;44(5):e9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma in a child.
  • Grossly, it resembled lymphangioma; however, histopathologic diagnosis was benign cystic mesothelioma (BCM), an entity that presents mainly in women of childbearing age.
  • He also underwent resection of a congenital cystic adenomatoid malformation of the right lung.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cystic Adenomatoid Malformation of Lung, Congenital / surgery. Diagnosis, Differential. Dyspnea / etiology. Humans. Infant. Lymphangioma / diagnosis. Male. Neoplasm Recurrence, Local / surgery. Pleural Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433159.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Granville L, Laga AC, Allen TC, Dishop M, Roggli VL, Churg A, Zander DS, Cagle PT: Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. Arch Pathol Lab Med; 2005 Nov;129(11):1428-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
  • OBJECTIVE: We address the current classifications and new changes regarding uncommon primary pleural tumors.
  • Primary pleural tumors are divided according to their behavior and are discussed separately as benign tumors, tumors of low malignant potential, and malignant neoplasms.
  • DATA SOURCES: Current literature concerning primary pleural neoplasms was collected and reviewed.
  • STUDY SELECTION: Studies emphasizing clinical, radiological, or pathologic findings of primary pleural neoplasms were obtained.
  • DATA EXTRACTION: Data deemed helpful to the general surgical pathologist when confronted with an uncommon primary pleural tumor was included in this review.
  • (1) benign, (2) low malignant potential, and (3) malignant.
  • A practical approach to the diagnosis of these neoplasms in surgical pathology specimens is offered.
  • The differential diagnosis, including metastatic pleural neoplasms, is also briefly addressed.
  • CONCLUSIONS: Uncommon primary pleural neoplasms may mimic each other, as well as mimic metastatic cancers to the pleura and diffuse malignant mesothelioma.
  • Correct diagnosis is important because of different prognosis and treatment implications for the various neoplasms.
  • [MeSH-major] Medical Oncology / methods. Mesothelioma / pathology. Neoplasm Metastasis / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Pleura / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Number-of-references] 131
  •  go-up   go-down


28. Fassina A, Fedeli U, Corradin M, Da Frè M, Fabbris L: Accuracy and reproducibility of pleural effusion cytology. Leg Med (Tokyo); 2008 Jan;10(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and reproducibility of pleural effusion cytology.
  • The increasing number of Malignant Mesothelioma (MM) cases that arrive for expert examinations to court for compensation reasons in subjects exposed to asbestos, in many instances rely exclusively on cytological smears of pleural effusion.
  • We evaluated the accuracy and reproducibility of cytological pleural effusions, based on morphological criteria alone.
  • Nine pathologists and eight residents from seven institutions in north-east Italy blindly examined 45 smears of MM (17), metastases (14) and benign effusions (14), in two rounds.
  • Diagnostic accuracy, interobserver and intraobserver agreement in the distinction of benign vs malignant cases, and in the differentiation of primary from metastatic malignancies, were evaluated.
  • The distinction of benign from malignant smears resulted rather satisfactory (k=0.514), but markedly decreased in differentiation of MM from metastases (overall agreement: k=0.343), as well as when readings from residents were analyzed (k=0.132).
  • Cytology is a useful and reliable tool in the identification of malignancies, but when the distinction of primary from metastatic tumors is addressed morphological criteria alone are not sufficient for a definite diagnosis of MM and the use of cell blocks, immunohistochemistry (IHC) and molecular ancillary techniques are recommended.
  • [MeSH-major] Mesothelioma / diagnosis. Neoplasm Metastasis / diagnosis. Pleural Effusion / pathology. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702624.001).
  • [ISSN] 1344-6223
  • [Journal-full-title] Legal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Leg Med (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


29. Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch; 2007 Apr;450(4):455-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
  • Cytology allows the diagnosis of malignant mesothelioma (MM) from effusions with high specificity but low sensitivity.
  • We studied whether the cytological diagnosis of MM could be improved by HA analysis.
  • HA was analysed in patients with histologically confirmed MM (n=162), adenocarcinoma or other malignant tumours (n=100) and in 90 patients with benign pleural diseases.
  • We conclude that the combined cytological and HA analysis of pleural effusions had the potential to improve the diagnosis of MM.
  • [MeSH-major] Hyaluronic Acid / analysis. Mesothelioma / diagnosis. Pleural Effusion / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 1977 May 2;76(3):357-61 [870264.001]
  • [Cites] Eur Respir J. 2004 Dec;24(6):1000-6 [15572545.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Jpn J Clin Oncol. 1997 Oct;27(5):293-7 [9390204.001]
  • [Cites] Arch Geschwulstforsch. 1985;55(4):259-64 [4037997.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):405-10 [11018693.001]
  • [Cites] Chest. 1988 Nov;94(5):1037-9 [3180855.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):68-73 [2731122.001]
  • [Cites] Eur Respir J. 2003 Mar;21(3):539-44 [12662014.001]
  • [Cites] Diagn Cytopathol. 1992;8(4):333-41 [1638933.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):445-7; discussion 448 [2635926.001]
  • [Cites] Eur Respir J. 1990 Oct;3(9):985-6 [2289567.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1406-10 [8111707.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Cancer. 1991 May 1;67(9):2410-4 [2013045.001]
  • [Cites] Thorax. 2003 Sep;58(9):809-13 [12947146.001]
  • (PMID = 17377812.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Azure Stains; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


30. Kayser K, Hoshang SA, Metze K, Goldmann T, Vollmer E, Radziszowski D, Kosjerina Z, Mireskandari M, Kayser G: Texture- and object-related automated information analysis in histological still images of various organs. Anal Quant Cytol Histol; 2008 Dec;30(6):323-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS: A generalized algorithm was developed that permits the evaluation of diagnosis-associated image features obtained from hematoxylin-eosin-stained histopathologic slides.
  • The procedure was tested for screening of tumor tissue vs. tumor-free tissue in 1,442 cases of various organs.
  • Tissue samples studied include colon, lung, breast, pleura, stomach and thyroid.
  • RESULTS: The accuracy of automated crude classification was between 95% and 100% based upon a learning set of 10 cases per diagnosis class.
  • The algorithm can also distinguish between benign and malignant tumors of colon, between epithelial mesothelioma and pleural carcinomatosis or between different common pulmonary carcinomas.
  • It is a promising technique that can assist tissue-based diagnosis and be expanded to virtual slide evaluation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160697.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Ruda TA, Dutta PK: Fenten chemistry of Fe(III)-exchanged zeolitic minerals treated with antioxidants. Environ Sci Technol; 2005 Aug 15;39(16):6147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Respirable mineral fibers, such as asbestos, are known to cause pleural mesothelioma, pulmonary fibrosis, and bronchial carcinoma, often years after exposure.
  • Erionite is carcinogenic, while mordenite is relatively benign.
  • [MeSH-minor] Asbestos / chemistry. Hydrogen Peroxide / chemistry. Lung Neoplasms / physiopathology. Mesothelioma / physiopathology. Oxidation-Reduction. Pulmonary Fibrosis / physiopathology

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. Erionite .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173575.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / Fenton's reagent; 12445-20-4 / mordenite; 12510-42-8 / erionite; 1318-02-1 / Zeolites; 1332-21-4 / Asbestos; 3352-57-6 / Hydroxyl Radical; BBX060AN9V / Hydrogen Peroxide; E1UOL152H7 / Iron
  •  go-up   go-down


32. Martínez Martínez P, Moldes Rodríguez M, Moreno Mata N, Simón Adiego C, Cebollero Presmanes M, González Aragoneses F: [Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura]. Cir Esp; 2007 Mar;81(3):155-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].
  • [Transliterated title] Inmunohistoquímica y vías de abordaje en el tumor fibroso pleural.
  • Solitary fibrous tumor of the pleura (SFTP) is a rare, benign, slow-growing neoplasm that arises from the submesothelial cells of the pleura.
  • Usually, resection of the tumor and adjacent structures are sufficient for resolution.
  • CD34 antigen positivity is a differential feature with mesothelioma.
  • Only four patients were symptomatic at diagnosis.
  • Because of the malignant potential of this tumor, long-term follow-up is mandatory.
  • [MeSH-major] Neoplasms, Fibrous Tissue / immunology. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / immunology. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted / instrumentation
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / immunology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mesothelioma / immunology. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349242.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


33. Neumann V, Löseke S, Tannapfel A: [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas]. Med Klin (Munich); 2009 Oct 15;104(10):765-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant peritoneal mesotheliomas arise mainly in male patients and the median age of initial diagnosis is about 56 years.
  • Asbestos exposure is the best-known and most common risk factor associated with the development of both pleural and peritoneal mesotheliomas and, therefore, about 90% of cases can be assessed as asbestos-associated.
  • Patients with peritoneal mesotheliomas have distinctly higher asbestos burden of the lungs than patients with pleural mesotheliomas.
  • The mean latency period between exposure and diagnosis of peritoneal mesothelioma ranges from 35 to 40 years and is comparable to that of pleural mesothelioma.
  • Mesothelioma of the tunica vaginalis testis also belongs to the group of peritoneal mesotheliomas.
  • No significant evidence exists for the classification of well-differentiated papillary mesothelioma, solitary fibrous tumor, adenomatoid tumor, primary peritoneal serous borderline tumor, and benign multicystic mesothelioma as asbestos-associated tumors.
  • [MeSH-major] Asbestosis / epidemiology. Mesothelioma / epidemiology. National Health Programs / statistics & numerical data. Peritoneal Neoplasms / epidemiology
  • [MeSH-minor] Biopsy. Causality. Cross-Sectional Studies. Female. Germany. Humans. Insurance, Accident / legislation & jurisprudence. Insurance, Accident / statistics & numerical data. Male. Middle Aged. Peritoneum / pathology. Pleural Neoplasms / classification. Pleural Neoplasms / epidemiology. Pleural Neoplasms / etiology. Pleural Neoplasms / pathology. Risk Factors. Workers' Compensation / legislation & jurisprudence. Workers' Compensation / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):403-6 [15737040.001]
  • [Cites] Environ Res. 1984 Dec;35(2):531-51 [6391911.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1067-87, vi [16325124.001]
  • [Cites] Am J Surg Pathol. 1990 Mar;14(3):230-9 [2305929.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):985-90 [17030547.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Oncol. 2008 Feb;31(1):49-54 [18376228.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Am J Gastroenterol. 1981 Apr;75(4):311-3 [7258177.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 1996;15(2-4):191-4 [9216805.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):134-9 [7237380.001]
  • [Cites] Environ Health. 2008 Jan 24;7:4 [18218073.001]
  • [Cites] Histopathology. 1991 Dec;19(6):515-22 [1786936.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 15;178(6):624-9 [18556631.001]
  • [Cites] Ultrastruct Pathol. 2002 Nov-Dec;26(6):355-63 [12537760.001]
  • [Cites] Am J Ind Med. 1988;14(3):331-9 [3189349.001]
  • [Cites] Histopathology. 2008 Jun;52(7):824-30 [18494612.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Int J Urol. 2008 Jun;15(6):560-1 [18489651.001]
  • [Cites] Chest. 1980 Feb;77(2):133-7 [7353405.001]
  • [Cites] Pathologe. 1999 May;20(3):169-76 [10412176.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):344-56 [7856747.001]
  • [Cites] Cancer. 1988 May 15;61(10):2019-21 [3282640.001]
  • [Cites] Am J Surg Pathol. 1988 Oct;12(10):737-46 [3421410.001]
  • [Cites] Nat Med. 1997 Aug;3(8):908-12 [9256284.001]
  • [Cites] Hum Pathol. 1977 Jan;8(1):83-94 [844856.001]
  • [Cites] Swiss Surg. 2003;9(6):311-4 [14725101.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):16-25 [16462153.001]
  • [Cites] Histopathology. 2009 Jan;54(1):55-68 [19054156.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] Histopathology. 2002 Mar;40(3):237-44 [11895489.001]
  • [Cites] J Occup Environ Med. 2003 Apr;45(4):451-5 [12708149.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1379-85 [8608519.001]
  • [Cites] Pathologe. 1989 Mar;10(2):114-7 [2717537.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):138-44 [17227115.001]
  • [Cites] Curr Opin Pulm Med. 1999 Sep;5(5):326-31 [10461539.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):393-6 [19390506.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):161-7 [15894368.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):10-7 [3025107.001]
  • [Cites] J Surg Oncol. 2008 Sep 15;98(4):268-72 [18726890.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Occup Environ Med. 1994 Dec;51(12):804-11 [7849863.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Am J Pathol. 1981 Mar;102(3):314-23 [7212016.001]
  • [Cites] Int Arch Occup Environ Health. 2001 Aug;74(6):383-95 [11563601.001]
  • [Cites] Cancer. 1975 Oct;36(4):1381-5 [1175135.001]
  • [Cites] Soz Praventivmed. 1982 Oct;27(5):220-2 [7158050.001]
  • [Cites] Occup Environ Med. 2007 Dec;64(12):839-42 [17567726.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(5):443-7 [2122588.001]
  • [Cites] Cancer Sci. 2006 Apr;97(4):292-5 [16630121.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):467-75 [1599025.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] World J Surg. 2006 Apr;30(4):560-6 [16547615.001]
  • [Cites] Chirurg. 2000 Aug;71(8):877-86 [11013806.001]
  • [Cites] Aktuelle Urol. 2006 Jul;37(4):281-3 [16878282.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1627-42 [18753943.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] Adv Anat Pathol. 2009 Jan;16(1):62-4 [19098468.001]
  • [Cites] Environ Health Perspect. 1983 Nov;53:121-30 [6662082.001]
  • (PMID = 19856150.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 76
  •  go-up   go-down


34. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


35. Goldberg M: Are lung and pleural benign asbestos induced diseases a preliminary step in the pathogenic process of mesothelioma and lung cancer development? Occup Environ Med; 2005 Oct;62(10):663-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are lung and pleural benign asbestos induced diseases a preliminary step in the pathogenic process of mesothelioma and lung cancer development?
  • [MeSH-major] Asbestosis / pathology. Lung Neoplasms / pathology. Mesothelioma / pathology. Pleural Diseases / pathology


36. Fletcher SV, Clark RJ: The Portsmouth thoracoscopy experience, an evaluation of service by retrospective case note analysis. Respir Med; 2007 May;101(5):1021-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsies were taken in 47 cases, 31 of which showed malignant mesothelioma.
  • Thirty seven percent of those without a history of direct exposure to asbestos had mesothelioma, implying that even in the absence of an exposure history a low threshold for investigation should be adopted for the local population.
  • Medical thoracoscopy is safe and effective in the diagnosis of benign and malignant pleural disease particularly in this high risk population.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Thoracoscopy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Asbestos / adverse effects. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Occupational Diseases / diagnosis. Occupational Diseases / etiology. Pleural Diseases / diagnosis. Pleural Effusion / etiology. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088053.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


37. Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A: Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol; 2009 Sep-Oct;11(5):369-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
  • AIM: The aim of this study was to assess the utility of dual time point 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) imaging in differentiating benign from malignant pleural disease.
  • METHODS: Fifty-five consecutive patients of suspected malignant pleural mesothelioma (MPM) and recurrence of MPM who were referred for the evaluation underwent two sequential 18F-FDG-PET scans (dual time point imaging).
  • Patients were divided into three principal groups (A = newly diagnosed MPM, B = recurrent MPM, and C = benign pleural disease).
  • The PET studies demonstrated 229 malignant pleural lesions in these patients.
  • The remaining 11 patients were proven to have benign pleural disease.
  • The mean +/- SD of the SUV(max1), SUV(max2), and Delta%SUV(max) in patients with both newly diagnosed and recurrent MPM were significantly higher than those of benign pleural disease group (p < 0.0001).
  • For each patient, the most intense (hottest) lesion's SUV(max1), SUV(max2), and Delta%SUV(max) were also compared among the aforementioned groups, and these results again confirmed that MPM lesions had significantly higher values than those of benign pleural lesions (p < 0.0001).
  • CONCLUSIONS: There is an increasing uptake of (18)F-FDG over time in pleural malignancies, whereas the uptake in benign pleural disease generally stays stable or decreases over time.
  • Therefore, dual time point imaging appears to be an effective approach in differentiating benign from malignant pleural disease, which increases the sensitivity and is also helpful in guiding the biopsy site for a successful diagnosis.
  • [MeSH-major] Fluorodeoxyglucose F18. Pleural Diseases / diagnostic imaging. Pleural Neoplasms / diagnostic imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Mesothelioma / diagnosis. Mesothelioma / diagnostic imaging. Mesothelioma / metabolism. Mesothelioma / pathology. Middle Aged. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mol Imaging Biol. 2009 Sep-Oct;11(5):294-5 [19319607.001]
  • [Cites] Chest. 1995 Jun;107(6 Suppl):345S-350S [7781416.001]
  • [Cites] Mayo Clin Proc. 1988 Dec;63(12):1234-44 [3059081.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1241-5 [10450672.001]
  • [Cites] Eur J Nucl Med. 1999 Oct;26(10 ):1345-8 [10541835.001]
  • [Cites] Eur J Nucl Med. 1999 Jan;26(1):22-30 [9933658.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jul;120(1):128-33 [10884665.001]
  • [Cites] Chest. 1995 Jun;107(6 Suppl):332S-344S [7781415.001]
  • [Cites] Chest. 1987 Jun;91(6):817-22 [3581930.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17 (4):377-83 [10773558.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):149-54 [15186594.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):370-4 [7790544.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] J Nucl Med. 2002 Jul;43(7):871-5 [12097455.001]
  • [Cites] Radiology. 1993 Aug;188(2):487-90 [8327702.001]
  • [Cites] Mol Imaging Biol. 2008 Jan-Feb;10(1):62-6 [18000713.001]
  • [Cites] Eur J Nucl Med. 1998 Jun;25(6):659-61 [9722421.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Jul;96(1):171-7 [3386291.001]
  • [Cites] Chest. 2002 Dec;122(6):1918-24 [12475827.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):983-1001, vii [15488553.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):995-8 [15181135.001]
  • [Cites] Semin Nucl Med. 2002 Oct;32(4):293-321 [12524653.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):963-8 [8610582.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):245-9 [10882281.001]
  • [Cites] Radiol Clin North Am. 2005 Jan;43(1):1-21, ix [15693644.001]
  • [Cites] J Nucl Med. 1994 Aug;35(8):1308-12 [8046485.001]
  • [Cites] Radiol Med. 1992 Jul-Aug;84(1-2):43-7 [1509143.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S73-6 [15261438.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1440-6 [16954551.001]
  • [Cites] Cancer. 2000 Dec 15;89(12 ):2547-54 [11135214.001]
  • [Cites] Am J Epidemiol. 1997 Feb 1;145(3):211-8 [9012593.001]
  • [Cites] Thorax. 1997 Feb;52(2):187-9 [9059484.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10 ):1317-23 [12271413.001]
  • [Cites] Ann Intern Med. 1991 Feb 15;114(4):271-6 [1987873.001]
  • [Cites] Radiology. 1993 Feb;186(2):297-309 [8421723.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):540-8 [12679397.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] J Nucl Med. 2001 Sep;42(9):1412-7 [11535734.001]
  • (PMID = 19472014.001).
  • [ISSN] 1860-2002
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


38. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers; 2007 Mar-Apr;12(2):214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
  • The present study was to evaluate MN/CA9 as a new molecular marker for the detection of cancer cells in pleural effusions.
  • Seventy-one pleural effusions including 59 malignant effusions from patients with cancer, and 12 patients with benign diseases as a control, were subjected to RT-PCR for detection of MN/CA9 gene expression.
  • MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 10/11 for other cancers).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Gene Expression. Humans. Neoplasm Proteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536770.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


39. Dejmek A: CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma. Acta Cytol; 2008 Sep-Oct;52(5):579-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
  • OBJECTIVE: To test the performance of CK5/6 for the differentiation between mesothelioma, adenocarcinoma and benign mesothelia/proliferations in effusion cytology.
  • STUDY DESIGN: CKS/6 immunocytochemistry was applied to ethanol-fixed cytospin preparations from 74 benign and malignant effusions.
  • RESULTS: Reactivity was seen in 7 of 8 mesotheliomas and in 9 of 11 benign mesothelial proliferations but also in 11 of l7 pulmonary adenocarcinomas and in 12 of 31 adenocarcinomas of nonpulmonary origin.
  • The high reactivity rate in pulmonary adenocarcinomas disagrees with the results obtained with histologic sections from solid tumor tissue, and CK5/6 seems to be of very limited value as an additional marker in effusion cytology.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Lung Neoplasms / metabolism. Mesothelioma / metabolism. Pleural Effusion / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833821.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-5; 0 / Keratin-6
  •  go-up   go-down


40. Inase N, Tominaga S, Yasui M, Tsukada Y, Oukouchi M, Miura H: [Adenosine deaminase 2 in the diagnosis of tuberculous pleuritis]. Kekkaku; 2005 Dec;80(12):731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosine deaminase 2 in the diagnosis of tuberculous pleuritis].
  • PURPOSE: We examined the usefulness of adenosine deaminase 2 (ADA2) in the diagnosis of tuberculous pleuritis.
  • SUBJECTS: A hundred cases, 78 male and 22 female, with pleural effusion were examined.
  • With regard to pleural effusion, 18 cases were transudate and 82 cases (9 tuberculous pleuritis, 27 lung cancer, 8 mesothelioma, 5 malignant diseases except lung cancer and mesothelioma, 5 benign asbestos pleurisy, 10 empyema, 10 parapneumonic effusion, one SLE, one parasitic infection, and 6 undetermined etiology) were exudates.
  • RESULTS: Pleural adenosine deaminase (ADA) was 90.4 +/- 22.4 U/l (mean +/- SD) and pleural ADA2 was 80.4 +/- 21.9 U/l in tuberculous pleuritis, both were significantly higher than those in non-tuberculous exudates (p < 0.001).
  • In the diagnosis of tuberculous pleuritis, pleural ADA showed 100% sensitivity and 88% specificity, whereas pleural ADA2 showed 100% sensitivity and 91% specificity.
  • CONCLUSION: Pleural ADA2 is useful in the diagnosis of tuberculous pleuritis, which has similar sensitivity and a little better specificity compared with pleural ADA.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Adenosine Deaminase / analysis. Transcription Factors / analysis. Tuberculosis, Pleural / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Enzyme Tests. Female. Humans. Isoenzymes. Male. Middle Aged. Pleural Effusion. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447785.001).
  • [ISSN] 0022-9776
  • [Journal-full-title] Kekkaku : [Tuberculosis]
  • [ISO-abbreviation] Kekkaku
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Isoenzymes; 0 / TADA2A protein, human; 0 / Transcription Factors; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


41. Lourenço R, Camacho R, Barata MJ, Canário D, Gaspar A, Cyrne C: CT-guided percutaneous transthoracic biopsy in the evaluation of undetermined pulmonary lesions. Rev Port Pneumol; 2006 Sep-Oct;12(5):503-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT-guided Percutaneous Transthoracic Biopsies (PTB) performed in the Radiology Department of Garcia de Orta Hospital between 2002 and 2004 to evaluate undetermined pulmonary lesions were retrospectively analysed.
  • 72 FNAB were considered adequate for cytology diagnosis; 72% of them positive for malignancy.
  • All malignant lesions were nodules: 20 adenocarcinoma, 13 non-small cell lung cancer (SCLC), 10 epidermoid tumours, 5 small-cell lung cancer, 2 carcinoids, 1 bronchiolo alveolar carcinoma, 1 malignant mesothelioma and 8 metastasis.
  • Unspecific/inflammatory lesions (n=5) were the most frequent benign lesions.
  • Spiculated and lobulated contour (p=0.05) were more prevalent in malignant lesions while regular contour was more frequent among benign lesions (p=0.0001).
  • Gender, smoking, location, pleural tag, homogenous attenuation, cavitation, calcification, necrosis and air bronchogram did not differ significantly between benign and malignant nodules.
  • [MeSH-major] Biopsy, Needle / methods. Lung Diseases / diagnosis. Lung Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117322.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


42. Tarrés J, Abós-Herràndiz R, Albertí C, Martínez-Artés X, Rosell-Murphy M, García-Allas I, Krier I, Castro E, Cantarell G, Gallego M, Orriols R: [Asbestos-related diseases in a population near a fibrous cement factory]. Arch Bronconeumol; 2009 Sep;45(9):429-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Enfermedad por amianto en una población próxima a una fábrica de fibrocemento.
  • MATERIAL AND METHODS: We retrospectively collected information available on patients with asbestos-related diseases who at the time of diagnosis had resided in the area near the fibrous cement factory.
  • Of the 1107 asbestos-related disease cases identified, 86.5% were benign and 8.4% pleural mesothelioma.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / epidemiology. Construction Materials. Environmental Exposure. Lung Neoplasms / epidemiology. Mesothelioma / epidemiology. Peritoneal Neoplasms / epidemiology. Pleural Neoplasms / epidemiology
  • [MeSH-minor] Aged. Female. Humans. Incidence. Male. Medical Records. Middle Aged. Occupational Exposure. Pleural Effusion / epidemiology. Pleural Effusion / etiology. Pleurisy / epidemiology. Pleurisy / etiology. Prevalence. Pulmonary Atelectasis / epidemiology. Pulmonary Atelectasis / etiology. Pulmonary Disease, Chronic Obstructive / epidemiology. Pulmonary Disease, Chronic Obstructive / etiology. Retrospective Studies. Risk. Spain. Time Factors

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501947.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


43. Gill RR, Gerbaudo VH, Jacobson FL, Trotman-Dickenson B, Matsuoka S, Hunsaker A, Sugarbaker DJ, Hatabu H: MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin N Am; 2008 May;16(2):319-39, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of benign and malignant pleural disease.
  • MR imaging serves as a problem-solving tool in the diagnosis of inflammatory and infectious pleural diseases and primary and secondary pleural malignancies.
  • Knowledge of MR imaging appearance of pleural diseases, including pleural effusions and empyema, benign and malignant pleural tumors, and especially mesothelioma, helps guide treatment decisions and surgical planning.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474335.001).
  • [ISSN] 1064-9689
  • [Journal-full-title] Magnetic resonance imaging clinics of North America
  • [ISO-abbreviation] Magn Reson Imaging Clin N Am
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA116271; United States / NCI NIH HHS / CA / R21CA116271-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


44. Nowak AK, Armato SG 3rd, Ceresoli GL, Yildirim H, Francis RJ: Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer; 2010 Oct;70(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
  • Imaging of malignant pleural mesothelioma (MPM) poses many challenges for imaging specialists and clinicians due to the anatomic location and unique growth pattern of this tumor.
  • Nevertheless, imaging in MPM plays a critical role in diagnosis, prognostication, prediction or measurement of response to therapy, and monitoring of disease recurrence after aggressive surgical management.
  • Imaging-based studies presented at the 9th International Conference of the International Mesothelioma Interest Group (IMIG) in October 2008 sought to further define the current practice and future potential of imaging for the mesothelioma patient.
  • These uses included FDG-PET imaging at the point of diagnosis, in prognostication, and in the assessment of response to chemotherapy.
  • At diagnosis, FDG-PET parameters had a high sensitivity and specificity for differentiation of benign from malignant pleural disease.
  • The use of FDG-PET to extract quantitative features from metabolically active tumor volume was shown to be a significant factor in the prediction of patient survival.
  • CT-based assessment of mesothelioma was determined to be inconsistent with spherical-model-based criteria so that changes in tumor area, a presumably more complete assessment of tumor burden, exhibited a 46% concordance rate with changes in linear measurements.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20541834.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102085
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Ireland
  •  go-up   go-down


45. García Gómez M, Artieda Pellejero L, Esteban Buedo V, Guzmán Fernández A, Camino Durán F, Martínez Castillo A, Lezzáun Goñi M, Gallo Fernández M, González García I, Martínez Arguisuelas N, Elvira Espinosa M, Sánchez de Navas AM, Zimmermann Verdejo M, Campos Acedo R, Galván Olivares F, Castañeda López R, Estaún Blasco E, Castell Salvá R, Martínez-Portillo LM, Rubio Sanz A, Unamuno Achúcarro A, Fernández Fernández I, Lama Herrera C, Mayoral Cortés JM: [Health surveillance of workers exposed to asbestos: an example of cooperation between the occupational prevention system and the national health system]. Rev Esp Salud Publica; 2006 Jan-Feb;80(1):27-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La Vigilancia de la Salud de los trabajadores expuestos al amianto: ejemplo de colaboracion entre el sistema de prevencion de riesgos laborales y el sistema nacional de salud.
  • 208 workers have COPD, 198 benign pleural disease, 8 lung cancer, 10 mesothelioma and 7 workers have other cancers possibly related to asbestos (gastric, larynx and colon cancer).

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16553258.001).
  • [ISSN] 1135-5727
  • [Journal-full-title] Revista española de salud pública
  • [ISO-abbreviation] Rev. Esp. Salud Publica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


46. Kurata S, Ishibashi M, Azuma K, Kaida H, Takamori S, Fujimoto K, Kobayashi M, Hirose Y, Aizawa H, Hayabuchi N: Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease. Jpn J Radiol; 2010 Jul;28(6):446-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
  • PURPOSE: The aim of this study was to compare the results of semiquantitative analysis by(18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) with plasma osteopontin levels in the same asbestos-related pleural disease population.
  • MATERIALS AND METHODS: A total of 17 patients with asbestos-related pleural disease were prospectively recruited.
  • The maximum standardized uptake value (SUVmax) was determined from the most active pleural lesion in each patient.
  • RESULTS: Malignant pleural mesothelioma (MPM) was histologically proven in 6 patients, and 11 patients had proven benign asbestos-related pleural diseases (7 pleural plaques, 4 asbestos pleurisy).
  • Significant differences in SUVmax were found between patients with MPM and those with asbestos pleurisy (P = 0.031) and between patients with MPM and those with pleural plaques (P = 0.012).
  • A significant difference was found in the plasma osteopontin levels between patients with asbestos pleurisy and patients with pleural plaques (Bonferroni correction, P = 0.024).
  • The SUVmax in patients with benign asbestos-related diseases was statistically positively correlated with plasma osteopontin in the same group (Spearman's r = 0.75, P < 0.05).
  • CONCLUSION: PET/CT might be more helpful than plasma osteopontin for distinguishing benign asbestos-related pleural diseases from MPM, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.
  • [MeSH-major] Asbestos / toxicity. Mesothelioma / diagnostic imaging. Osteopontin / blood. Pleural Diseases / diagnostic imaging. Positron-Emission Tomography / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Pleura / diagnostic imaging. Pleural Neoplasms / blood. Pleural Neoplasms / diagnostic imaging. Pleurisy / blood. Pleurisy / diagnostic imaging. Prospective Studies. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):266-9 [12400973.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Dec;14(6):479-88 [14563350.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1551-5 [11585872.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1362-6 [19174489.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jun;129(6):1364-70 [15942579.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):35-45 [17204697.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1144-9 [12215551.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17 (4):377-83 [10773558.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6 [12878934.001]
  • [Cites] Thorac Cardiovasc Surg. 2009 Jun;57(4):217-21 [19670115.001]
  • [Cites] Exp Oncol. 2004 Sep;26(3):179-84 [15494684.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):995-8 [15181135.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Radiol Clin North Am. 1992 Nov;30(6):1177-89 [1410307.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • (PMID = 20661695.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


47. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


48. Qureshi NR, Gleeson FV: Imaging of pleural disease. Clin Chest Med; 2006 Jun;27(2):193-213
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of pleural disease.
  • Imaging plays an important role in the diagnosis and subsequent management of patients with pleural disease.
  • The presence of a pleural abnormality is usually suggested following a routine chest x-ray, with a number of imaging modalities available for further characterization.
  • This article describes the radiographic and cross-sectional appearances of pleural diseases, which are commonly encountered in every day practice.
  • The conditions covered include benign and malignant pleural thickening, pleural effusions, empyema and pneumothoraces.
  • [MeSH-major] Pleural Diseases / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Biopsy. Humans. Magnetic Resonance Imaging. Mesothelioma / pathology. Mesothelioma / radiography. Pleural Effusion / pathology. Pleural Effusion / radiography. Pleural Neoplasms / pathology. Pleural Neoplasms / radiography. Pleural Neoplasms / secondary. Pneumothorax / pathology. Pneumothorax / radiography. Pulmonary Atelectasis / pathology. Pulmonary Atelectasis / radiography. Radiographic Image Enhancement

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716813.001).
  • [ISSN] 0272-5231
  • [Journal-full-title] Clinics in chest medicine
  • [ISO-abbreviation] Clin. Chest Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 115
  •  go-up   go-down


49. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T: IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol; 2010 May;41(5):745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
  • Differentiating reactive mesothelial cells from metastatic carcinoma and malignant mesothelioma is critical in effusion cytology.
  • Numerous immunohistochemical/cytochemical reports use various antibodies in effusion samples, and most antibodies differentiate metastatic adenocarcinoma from malignant mesothelioma, but no antibodies help distinguish malignant mesothelioma from reactive mesothelial cells.
  • A total of 229 cases of pleural and peritoneal effusion cytospecimens were evaluated for the study, including 39 benign effusions with reactive mesothelial cells and 190 metastatic malignant effusions.
  • IMP3 immunoreactivity was observed in 2 (5.1%) of 39 cases of reactive mesothelial cells, 138 (72.6%) of 190 cases of malignant effusion, 4 (36.4%) of 11 cases of malignant mesothelioma, 106 (75.7%) of 140 cases of metastatic adenocarcinoma, and 8 (100%) of 8 cases of squamous cell carcinoma.
  • The overall specificity for the diagnosis of malignancy was 94.9%, whereas the sensitivity was 72.6%.
  • In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%.
  • However, the IMP3 antibody is a highly specific marker for malignant lesions, and thus, IMP3 staining is useful for distinguishing neoplastic cells from reactive mesothelial cells in effusion samples.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Biomarkers, Tumor / metabolism. Mesothelioma / metabolism. Neoplasm Proteins / metabolism. Pleural Effusion, Malignant / metabolism. RNA-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20060157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


50. Ladanyi M: Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer; 2005 Jul;49 Suppl 1:S95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of P16/CDKN2A deletion in pleural mesotheliomas.
  • In terms of diagnostic applications, its high prevalence makes it a useful marker to distinguish malignant mesothelial cells from benign reactive ones in pleural fluid cytologic preparations.
  • The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.
  • Finally, global gene expression profiling using Affymetrix U133A chips finds few gene expression correlates of P16/CDKN2A deletion in pleural mesothelioma, consistent with its non-transcriptional mode of direct action through regulation of cell cycle-related kinase signaling.
  • [MeSH-major] Genes, p16 / physiology. Mesothelioma / genetics. Pleural Neoplasms / genetics
  • [MeSH-minor] Cytological Techniques. Gene Deletion. Gene Expression Profiling. Humans. Pleural Effusion, Malignant. Prognosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15950811.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 5
  •  go-up   go-down


51. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Mesothelioma / metabolism. Pleural Effusion, Malignant / metabolism. Receptors, Laminin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


52. Greillier L, Astoul P: Mesothelioma and asbestos-related pleural diseases. Respiration; 2008;76(1):1-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma and asbestos-related pleural diseases.
  • Consequently, pulmonologists are still dealing with consequences of asbestos exposure, which mainly occur at the pleural surface.
  • The aim of this review is to provide an overview of asbestos-related pleural diseases.
  • We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis.
  • Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area.
  • [MeSH-major] Asbestosis. Mesothelioma. Pleural Diseases. Pleural Neoplasms

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18583923.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 189
  •  go-up   go-down


53. Liubchenko PN, Viatkina EI, Dubrova SE: [Case of asbestosis with massive benign pleural involvement]. Med Tr Prom Ekol; 2007;(4):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of asbestosis with massive benign pleural involvement].
  • Nodular masses in pleura revealed on pulmonary CT scans were considered as malignant mesothelioma.
  • For diagnosis verification, videothoracoscopy with target biopsy of the nodes was performed.
  • Histologic diagnosis - fragments of dense fibrous connective tissue.
  • FINAL DIAGNOSIS: Asbestosis, s/s, p/p, 2/2.
  • Pleural asbestosis.
  • [MeSH-major] Asbestosis / diagnosis. Pleural Diseases / diagnosis. Thoracoscopy / methods

  • Genetic Alliance. consumer health - Asbestosis.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663051.001).
  • [ISSN] 1026-9428
  • [Journal-full-title] Meditsina truda i promyshlennaia ekologiia
  • [ISO-abbreviation] Med Tr Prom Ekol
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


54. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med; 2010 Mar 15;181(6):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
  • RATIONALE: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM).
  • METHODS: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85).
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075387.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


55. Deniz H, Kibar Y, Güldür ME, Bakir K: Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract; 2009;205(11):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
  • Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis.
  • It has also been suggested to be useful in identifying the mesothelial differentiation.
  • The aim of this study is to compare D2-40 immunostaining in MM, pulmonary adenocarcinoma, and benign mesothelial proliferations.
  • In this retrospective study, D2-40 immunostaining was investigated in 37 cases of MM, 36 cases of pulmonary adenocarcinoma, and 31 cases of benign mesothelial proliferation.
  • The diagnosis of MM had previously been confirmed by a panel including calretinin, CK5/6, and CEA.
  • Predominantly membranous immunoreactivity was observed in 51% of MMs and in 55% of benign mesothelial proliferations.
  • We believe that D2-40 may be helpful in the differential diagnosis of MM from pleural involvement of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Lung / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pleura / metabolism. Pleural Neoplasms / diagnosis. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573998.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


56. Cakir E, Demirag F, Aydin M, Unsal E: Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Diagn Cytopathol; 2009 Jan;37(1):4-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
  • Distinguishing malignant mesothelioma, adenocarcinoma and reactive mesothelial proliferation in both cytologic and surgical pathologic specimens is often a diagnostic challenge.
  • Conventional cytomorphologic assessment is an important step in the differential diagnosis of these entities.The pleural effusion cytologies from 40 cases of malignant mesothelioma, 40 cases of adenocarcinoma and 30 cases of reactive mesothelial proliferation diagnosed between 1997 and 2007 were reviewed.
  • Twenty-seven cytologic features which are regarded as useful in the differential diagnosis of mesothelioma, adenocarcinoma and benign mesothelial proliferation were assessed.
  • Three features were selected to distinguish malignant mesothelioma from adenocarcinoma: giant atypical mesothelial cell (P = 0.0001), nuclear pleomorphism (P = 0.0001) and acinar structures (P = 0.0001), the latter two being characteristics of adenocarcinoma.
  • The variables selected to differentiate malignant mesothelioma from reactive mesothelial cells were: cell ball formation (P = 0.0001), cell in cell engulfment (P = 0.0001) and monolayer cell groups (P = 0.0001), the latter being a feature of benign mesothelial proliferation.
  • When these selected variables were subjected to a stepwise logistic regression analysis, the logistic model correctly predicted 90% of cases of benign mesothelial proliferation versus 97.5% of malignant mesothelioma and 92.5% of malignant mesothelioma versus 92.5% of adenocarcinoma.Conventional cytomorphologic assessment is the first step to establish an accurate diagnosis in pleural effusions.
  • Several cytologic features have predictive value to separate malignant mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mesothelioma / diagnosis. Neoplasms, Mesothelial / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Logistic Models

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973123.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Mocanu L, Cîmpean AM, Raica M: Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions. Rom J Morphol Embryol; 2006;47(4):351-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions.
  • Pleural effusions occur in many benign and malignant conditions.
  • The differentiation of mesothelial hyperplasia, malignant epithelial mesothelioma and metastatic adenocarcinoma in cytologic specimens is often difficult.
  • Because many immunohistochemical studies had suggested that HBME-1 has a high sensibility but a low specificity for mesothelial differentiation, the authors investigate its utility in cytological specimens.
  • In this study, immunostaining was performed on 30 smears from seven patients with inflammatory pleural effusions, 21 patients with metastatic pleural effusions and two patients with malignant epithelial mesothelioma.
  • Benign mesothelial cells expressed HBME-1 in 13 (46.43%) cases with thick and thin membrane pattern and with thin membrane and cytoplasmic pattern in 11 (39.29%) cases.
  • One of the malignant mesothelioma was positive for HBME-1 with thick and thin membrane pattern.
  • Metastatic tumor cells were positive for HBME-1 in seven (33.33%) cases; the staining pattern in metastatic adenocarcinoma cells was thin membrane and focal cytoplasmic.
  • HBME-1 has a moderate sensibility and specificity for mesothelial cells and can be used as part of a panel for differentiation of malignant and reactive mesothelial cells from adenocarcinoma in pleural effusions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392981.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen
  •  go-up   go-down


58. Zeren EH, Demirag F: Benign and Malignant Mesothelial Proliferation. Surg Pathol Clin; 2010 Mar;3(1):83-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and Malignant Mesothelial Proliferation.
  • Malignant mesothelioma (MM) is a rare primary malignant tumor of the surface serosal cells.
  • The diagnosis of MM is challenging with a broad differential diagnosis.
  • For many decades, studies have focused on distinguishing MM from other types of cancer; however, benign mesothelial cell hyperplasia, especially in small biopsies, has emerged as a major problem.
  • The features of pleural lesions are somewhat different from peritoneal diseases, and this article primarily focuses on pleural diseases.
  • Thorough interpretation and correlation of clinical, radiologic, and pathologic findings are essential for a correct diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 26839028.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Malignant mesothelioma / Mesothelial proliferations / Metastatic carcinoma / Pleural effusion
  •  go-up   go-down


59. Ameille J, Brochard P, Letourneux M, Paris C, Pairon JC: [Asbestos-related cancer risk in the presence of asbestosis or pleural plaques]. Rev Mal Respir; 2009 Apr;26(4):413-21; quiz 480, 483
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos-related cancer risk in the presence of asbestosis or pleural plaques].
  • [Transliterated title] Risque de cancer lié à l'amiante en présence d'asbestose ou de plaques pleurales.
  • INTRODUCTION: The relationships between benign asbestos-related diseases (asbestosis and pleural plaques) and thoracic cancers are still debated.
  • In subjects with occupational exposure to asbestos, an increased risk of lung cancer and pleural mesothelioma is observed in subjects with pleural plaques on chest x-ray, in comparison with the general population.
  • In exposed subjects with similar cumulative exposure to asbestos, it is not demonstrated that pleural plaques are associated with an increased risk of lung cancer or pleural mesothelioma.
  • CONCLUSION: In the present state of knowledge, isolated pleural plaques do not justify specific medical surveillance, as compared to that required by the mere estimated cumulative exposure to asbestos.
  • [MeSH-major] Asbestosis / complications. Lung Neoplasms / etiology. Mesothelioma / etiology. Occupational Exposure. Pleural Diseases / etiology


60. Jenkins LA, O-Yurvati AH: Solitary fibrous pleural tumor. J Am Osteopath Assoc; 2008 Jun;108(6):307-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous pleural tumor.
  • Solitary fibrous pleural tumors are rare masses of mesenchymal origin that may be mistaken for mesothelioma.
  • A positive staining of vimentin, negative staining of cytoplasmic keratin, and expression of the CD34 antigen can confirm the presence of a solitary fibrous pleural tumor.
  • Although most tumors of this type are benign, they possess a malignant potential and thus should be excised.
  • Further testing after excision revealed a solitary fibrous pleural tumor.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587079.001).
  • [ISSN] 1945-1997
  • [Journal-full-title] The Journal of the American Osteopathic Association
  • [ISO-abbreviation] J Am Osteopath Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S: Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest; 2010 Jun;137(6):1362-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
  • BACKGROUND: In cases of pleural effusion, tissue samples can be obtained through Abrams needle pleural biopsy (ANPB), thoracoscopy, or cutting-needle pleural biopsy under the guidance of CT scan (CT-CNPB) for histopathologic analysis.
  • This study aimed to compare the diagnostic efficiency and reliability of ANPB under CT scan guidance (CT-ANPB) with that of medical thoracoscopy in patients with pleural effusion.
  • METHODS: Between January 2006 and January 2008, 124 patients with exudative pleural effusion that could not be diagnosed by cytologic analysis were included in the study.
  • RESULTS: Of the 124 patients, malignant mesothelioma was diagnosed in 33, metastatic pleural disease in 47, benign pleural disease in 42, and two were of indeterminate origin.
  • No difference was identified between the sensitivities of the two methods based on the cause, the CT scan findings, and the degree of pleural thickening.
  • CONCLUSION: We recommend the use of CT-ANPB as the primary method of diagnosis in patients with pleural thickening or lesions observed by CT scan.
  • In patients with only pleural fluid appearance on CT scan and in those who may have benign pleural pathologies other than TB, the primary method of diagnosis should be medical thoracoscopy.
  • [MeSH-major] Biopsy, Needle / methods. Mesothelioma / diagnosis. Pleural Effusion / diagnosis. Pleural Neoplasms / diagnosis. Radiography, Interventional. Thoracoscopy. Tomography, X-Ray Computed
  • [MeSH-minor] Chi-Square Distribution. Contrast Media. Female. Humans. Male. Middle Aged. Pleural Effusion, Malignant / diagnosis. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154079.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00720954
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


62. Liu J, He JX, Cai CJ, Chen HZ, Wei B, Shao WL, Li SB: [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun;33(6):432-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura].
  • OBJECTIVE: To report the characteristics of solitary fibrous tumor of the pleura (SFTP), and to analyze the factors associated with the misdiagnosis of this disease.
  • RESULTS: The preoperative diagnosis was pleural mesothelioma in 7 cases, neurogenic tumor in 6, lung cancer in 4, SFTP in 2, hilar lymph node tuberculosis in 1 and inflammatory granuloma in 1 case.
  • All the cases underwent radical resection, and postoperative pathology and immunohistochemical study were performed, and the diagnosis of benign solitary fibrous tumor of the pleura was confirmed.
  • CONCLUSION: The recognition of the clinical characteristics of pleural solitary fibrous tumor is essential for improving the diagnosis of this uncommon disease.
  • [MeSH-major] Diagnostic Errors. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979815.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med; 2006 May 15;173(10):1155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
  • BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue.
  • Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet.
  • METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma.
  • FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L).
  • The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%).
  • The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%).
  • SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L).
  • The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%).
  • The AUC for pleural SMRP-differentiating metastasis and mesothelioma was 0.793.
  • INTERPRETATION: We show that SMRPs may be a promising marker for mesothelioma diagnosis when measured either in serum or pleural fluid.
  • The diagnostic value of SMRPs was similar in both types of samples, but pleural fluid SMRPs may better discriminate mesothelioma from pleural metastasis.
  • [MeSH-major] Asbestosis / pathology. Membrane Glycoproteins / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / pathology. Sialoglycoproteins / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease Progression. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Osteopontin. Prognosis. Prospective Studies. Sensitivity and Specificity. Solubility. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456138.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


64. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • The subcutis is a particularly rare site of metastatic sarcomatoid mesothelioma.
  • It is essential to differentiate neoplasm metastatic to the skin and subcutis from primary and benign lesions of the same region.
  • FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


65. Kotoulas C, Fotinou M, Tsaroucha E, Konstantinou M, Lioulias A: Images in cardiothoracic surgery. Localized fibrous mesothelioma: an extremely rare benign pleural tumor. Ann Thorac Surg; 2006 Jun;81(6):2316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in cardiothoracic surgery. Localized fibrous mesothelioma: an extremely rare benign pleural tumor.
  • [MeSH-major] Mesothelioma / radiography. Pleural Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731187.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Wu M, Sun Y, Li G, Desman G, Wang B, Gil J, Burstein DE: Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol; 2007 Nov;128(5):783-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
  • We examined benign and malignant mesothelial tissue samples for the presence of X-linked inhibitor of apoptosis protein (XIAP), a potent constituent of the inhibitor of apoptosis family of caspase inhibitors.
  • We subjected 55 sections (31 malignant mesotheliomas, 2 well-differentiated peritoneal mesotheliomas, 13 pleural mesothelial hyperplasias, and 9 benign mesothelial tissues) from archival formalin-fixed, paraffin-embedded surgical tissue blocks to citrate-based antigen retrieval and then incubated them with monoclonal anti-XIAP (clone 48, dilution 1:250; BD Biosciences, San Jose, CA) at 4 degrees C for 72 hours and developed them using EnVision-Plus reagents (DAKO, Carpinteria, CA) and diaminobenzidine as the chromogen.
  • All 9 normal mesothelial samples were negative for XIAP.
  • Of 13 mesothelial hyperplasias, 1 (8%) was weakly positive in fewer than 10% of cells, as was 1 of 2 well-differentiated peritoneal mesotheliomas.
  • XIAP immunostaining, when strong, allows for distinction of malignant from benign and hyperplastic mesothelial cell populations and is a potentially useful immunodiagnostic marker in small samples and morphologically controversial cases.
  • Elevated expression of XIAP could contribute to tumorigenesis in mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelium / chemistry. Immunohistochemistry / methods. Mesothelioma / chemistry. Peritoneal Neoplasms / chemistry. Precancerous Conditions / chemistry. X-Linked Inhibitor of Apoptosis Protein / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951200.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


67. Mazzetti L, Murer B, Quintavalle S, Zeni E, Miotto D, Mapp CE, De Rosa E, Boschetto P: [Lung cancer in a female non-smoker with occupational exposure to asbestos: a case report]. Med Lav; 2006 Jul-Aug;97(4):581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Workers exposed to asbestos may develop lung and pleural diseases such as asbestosis, lung cancer, benign pleural effusion, pleural plaques and mesothelioma.
  • She had benign pleural effusion, pleural plaques, asbestosis and lung cancer.


68. Morokawa N, Takayanagi N, Ubukata M, Kurashima K, Yoned K, Tsuchiy N, Miyahara Y, Yamaguchi S, Tokunaga D, Saito H, Yanagisawa T, Sugita Y, Kawabata Y: [Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy]. Nihon Kokyuki Gakkai Zasshi; 2008 May;46(5):368-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy].
  • His chest CT showed bilateral pleural thickening and pleural effusion.
  • The pleural effusion of the right thorax exhibited both elevated level of adenosine deaminase and increased numbers of lymphocytes.
  • Progressive bilateral pleural thickening were found on chest CT, and pulmonary function tests showed severe restrictive ventilatory impairments since 1998.
  • Thoracoscopic pleural biopsy was conducted in 2001 to exclude pleural malignant mesothelioma.
  • No malignancy was found in pleural samples.
  • After 3-year observation and excluding other causes, he was given a diagnosis of benign asbestos pleurisy.
  • We suspected that diffuse pleural thickening could be a major cause of fatal respiratory impairment in this case.
  • [MeSH-major] Asbestos / adverse effects. Occupational Diseases / etiology. Occupational Diseases / pathology. Occupational Exposure / adverse effects. Pleura / pathology. Pleurisy / etiology. Pleurisy / pathology. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18517012.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


69. Abú-Shams K, Boldú J, Tiberio G, Tabar A, Fernández Infante B, Labarta N: [Registry of occupational respiratory diseases in Navarre]. An Sist Sanit Navar; 2005;28 Suppl 1:135-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Registro de enfermedades respiratorias de origen laboral en Navarra.
  • This database has several variables: gender, age, tobacco habit, hospital department and notifying doctor, diagnosis, job and causal agent.
  • The diagnoses were: 50 bronchial asthma (40%), 31 benign pleural disease (24.8%), 8 extrinsic allergic alveolitis (6.4%), 8 mesothelioma (6.4%), 7 bronchopulmonary cancer (5.6%), 5 acute inhalations (4%), 3 amianthinopsy (2.4%), 2 rhinitis (1.6%), 1 RADS (0.8%) and 1 COPD (0.8%).
  • CONCLUSIONS: The most frequent pathology was bronchial asthma, followed by benign pleural disease.
  • The Pneumology Service of the Virgen del Camino Hospital reported most of the cases.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915181.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


70. Salahudeen HM, Hoey ET, Robertson RJ, Darby MJ: CT appearances of pleural tumours. Clin Radiol; 2009 Sep;64(9):918-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT appearances of pleural tumours.
  • Computed tomography (CT) is the imaging technique of choice for characterizing pleural masses with respect to their location, composition, and extent.
  • A spectrum of tumours can affect the pleura of which metastatic adenocarcinoma is the commonest cause of malignant pleural disease, while malignant mesothelioma is the most common primary pleural tumour.
  • Certain CT features help differentiate benign from malignant processes.
  • This pictorial review highlights the salient CT appearances of a range of tumours that may affect the pleura.
  • [MeSH-major] Pleural Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Aged. Asbestos / adverse effects. Female. Fibroma / radiography. Humans. Lipoma / radiography. Lymphoma / radiography. Male. Mesothelioma / pathology. Mesothelioma / radiography. Neoplasm Staging / methods. Occupational Exposure / adverse effects. Pleura / anatomy & histology. Pleura / radiography. Sarcoma / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664483.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 95
  •  go-up   go-down


71. Ohar JA, Ampleford EJ, Howard SE, Sterling DA: Identification of a mesothelioma phenotype. Respir Med; 2007 Mar;101(3):503-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a mesothelioma phenotype.
  • Despite the strong association of asbestos exposure to mesothelioma, only a fraction of persons exposed develop this neoplasm which is characterized by long latency and shortened survival.
  • Familial clustering implicates both exposure and genetic predisposition as causative, but a biologically relevant mesothelioma phenotype essential to genetic analysis has not been defined.
  • To identify a more extensive set of traits that would define a mesothelioma phenotype for the purpose of genetic analysis, we set to determine characteristics that distinguish mesothelioma patients from others exposed to asbestos and to identify factors that predict the presence of mesothelioma over other mesenchymal tumors of the peritoneum and carcinoma metastatic to the pleura.
  • We compared demographics in four asbestos-exposed groups (controls n=347, bronchogenic cancer n=67, mesothelioma n=179 and benign asbestos-induced lung disease (BALD) n=3757).
  • Within the mesothelioma group, we compared traits to identify characteristics associated with shortened survival.
  • We found that compared to other asbestos-exposed groups, subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a second cancer diagnosis (odds ratio=3.29), had a longer disease latency, and had a greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI 2.5-3.5).
  • Thoracic tumor location, work exposure and male gender were consistently associated with shortened survival (1.9+/-1.3 years).
  • We conclude that thoracic tumor location, work exposure, male gender, long latency, early age at first exposure, presence of a second cancer, and first-degree relative with cancer define a phenotype that sets mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / genetics. Occupational Diseases / genetics
  • [MeSH-minor] Age Factors. Aged. Educational Status. Family Health. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Occupational Exposure / adverse effects. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / mortality. Phenotype. Pleural Neoplasms / genetics. Pleural Neoplasms / mortality. Risk Factors. Sex Factors. Smoking / adverse effects


72. Chapman EA, Thomas PS, Yates DH: Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res; 2010 Sep;4(3):034001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several diseases occur due to asbestos exposure, including malignant tumours such as malignant mesothelioma of the pleura and lung cancer, which have a very poor prognosis.
  • Asbestos inhalation may also result in more benign conditions such as asbestosis (or pulmonary fibrosis due to asbestos), pleural plaques and pleural thickening.
  • [MeSH-major] Asbestos / analysis. Asbestosis / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383477.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 1332-21-4 / Asbestos
  •  go-up   go-down


73. Aziz F: Radiological Findings in a case of Advance staged Mesothelioma. J Thorac Dis; 2009 Dec;1(1):46-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological Findings in a case of Advance staged Mesothelioma.
  • Chest X Ray is the initial screening test for the mesothelioma like all other the chest diseases.
  • But computed tomography (CT) is the imaging technique of choice for charactering pleural masses.
  • Certain CT features help differentiate benign from malignant processes.
  • This short article highlights the salient CT appearance of mesothelioma; the most common pleural tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22263002.001).
  • [ISSN] 2072-1439
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3256484
  • [Keywords] NOTNLM ; Advance staged Mesothelioma / Radiological Findings
  •  go-up   go-down


74. Butnor KJ: My approach to the diagnosis of mesothelial lesions. J Clin Pathol; 2006 Jun;59(6):564-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to the diagnosis of mesothelial lesions.
  • Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies.
  • Immunohistochemical markers can aid in distinguishing epithelioid malignant mesothelioma from metastatic adenocarcinoma, but because no single marker reliably separates all cases, a panel of stains is recommended.
  • Immunohistochemical studies are of more limited value in sarcomatoid malignant mesothelioma, and other features often play an essential role.
  • The separation of reactive mesothelial proliferations from malignant mesothelioma on small biopsy can be quite difficult, as distinguishing features, such as stromal invasion, often cannot be adequately assessed.
  • In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Humans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):25-30 [9253621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1399-408 [9414183.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):85-9 [9426522.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):166-9 [9490276.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):73-8 [9500194.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):285-92 [9580050.001]
  • [Cites] Histopathology. 1998 Mar;32(3):209-16 [9568505.001]
  • [Cites] Histopathology. 1998 May;32(5):462-72 [9639123.001]
  • [Cites] Histopathology. 2000 Sep;37(3):224-31 [10971698.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1545-9 [11090371.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1316-20 [11570906.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Arch Pathol Lab Med. 2001 Dec;125(12):1588-90 [11735696.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):191-9 [9704618.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):182-8 [9754650.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1215-21 [9777983.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):929-33 [9796717.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):313-23 [10088551.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):105-10 [15389250.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Thorac Imaging. 2003 Jul;18(3):200-3 [12867819.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):444-52 [14636270.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):534-40 [15087673.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] Am J Clin Pathol. 1976 Feb;65(2):159-67 [175652.001]
  • [Cites] Am J Pathol. 1982 Jul;108(1):80-8 [6178295.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):215-22 [7102900.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):62-6 [3099726.001]
  • [Cites] Pathol Annu. 1987;22 Pt 2:91-131 [2825103.001]
  • [Cites] Ultrastruct Pathol. 1987;11(5-6):503-33 [3318058.001]
  • [Cites] Ultrastruct Pathol. 1988;12(4):367-84 [2458647.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:303-53 [2654842.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 2000 Apr;36(4):341-7 [10759948.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):759-66 [2193875.001]
  • [Cites] Histopathology. 1992 Jan;20(1):47-51 [1310669.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):295-8 [1577967.001]
  • [Cites] Histopathology. 1992 Nov;21(5):453-7 [1280615.001]
  • [Cites] Histopathology. 1993 Jun;22(6):601-2 [8354495.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):753-7 [7520015.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):30-44 [7770673.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):189-94 [8607443.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1037-46 [8764740.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1147-52 [8822117.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9 [15722797.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):34-48 [16056246.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1203-14 [9777982.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):649-54 [10800396.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] J Postgrad Med. 2002 Jan-Mar;48(1):29-31 [12082324.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Histopathology. 2002 Oct;41(4):301-7 [12383211.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3443-8 [12552937.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):29-34 [10665909.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):107-12 [10697265.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):598-606 [10757409.001]
  • (PMID = 16731600.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1860395
  •  go-up   go-down


75. Giesel FL, Bischoff H, von Tengg-Kobligk H, Weber MA, Zechmann CM, Kauczor HU, Knopp MV: Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest; 2006 Jun;129(6):1570-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
  • The aims of this study were to evaluate the feasibility of DCE-MRI in malignant pleural mesothelioma (MPM), to differentiate benign from pathologic tissue and compare pharmacokinetic with clinical parameters and survival in order to map out its microcirculation; and to compare pharmacokinetic with clinical parameter and survival in order to improve our understanding of the in vivo biology of this malignancy.
  • METHODS: Nineteen patients with a diagnosis of MPM who were scheduled to receive chemotherapy with gemcitabine were enrolled in the study.
  • Tumor regions were characterized by the pharmacokinetic parameters amplitude (Amp), redistribution rate constant (kep), and elimination rate constant (kel).
  • Kinetic parameters of tumor tissue and normal tissue were compared using the Student t test.
  • RESULTS: Normal and tumor tissue could be distinguished by the pharmacokinetic parameters Amp and kel (p </= 0.001).
  • Clinical responders had a median kep value within the tumor of 2.6 min, while nonresponders showed a higher value (3.6 min), which coincided with longer survival (780 days vs 460 days).
  • CONCLUSIONS: DCE-MRI can be used in patients with MPM to assess tumor microvascular properties and to demonstrate tumor heterogeneity for therapy monitoring.
  • High pretherapeutic values of kep within the tumor correlated with a poor overall response to therapy.
  • [MeSH-major] Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Magnetic Resonance Imaging. Mesothelioma / metabolism. Mesothelioma / pathology. Pleural Neoplasms / metabolism. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778277.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Contrast Media; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


76. Chung CT, Santos Gda C, Hwang DM, Ludkovski O, Pintilie M, Squire JA, Tsao MS: FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol; 2010 Jul;63(7):630-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
  • AIMS: To develop a fluorescence in-situ hybridisation (FISH) assay for detecting p16/CDKN2A deletion on paraffin tissue sections for use as an ancillary test to distinguish reactive from malignant mesothelial proliferations.
  • METHOD: Dual-colour FISH for p16/CDKN2A and chromosome 9 (CEP-9) was performed on 11 benign mesothelial proliferations and 54 malignant pleural mesothelioma (MPM) cases to establish cut-off values for p16/CDKN2A deletion.
  • RESULTS: Cut-off values for p16/CDKN2A deletion were calculated based on FISH signalling patterns obtained from the benign controls (mean percent nuclei plus three standard deviations).
  • None of the benign cases showed a homozygous deletion pattern (no p16/CDKN2A, at least one CEP-9 signal).
  • CONCLUSION: Distinction between benign and malignant mesothelial proliferations can be diagnostically challenging.
  • FISH for p16/CDKN2A deletion is a useful test for confirming the diagnosis of MPM.
  • [MeSH-major] Gene Deletion. Genes, p16. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4547-51 [12907630.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] J Pathol. 2003 Nov;201(3):355-62 [14595746.001]
  • [Cites] J Pathol. 1992 May;167(1):1-4 [1320670.001]
  • [Cites] Virchows Arch. 2008 Dec;453(6):627-35 [18958493.001]
  • [Cites] J Pathol. 1992 Dec;168(4):377-81 [1484319.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Hum Pathol. 1994 May;25(5):443-8 [8200637.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5547-51 [7923195.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):511-5 [7630635.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):649-53 [9466670.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):143-8 [15571800.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3303-8 [15867227.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):320-4 [16240396.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Histopathology. 2006 Dec;49(6):561-8 [17163840.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):215-20 [17192790.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):742-7 [18327208.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):51-6 [12589646.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] J Pathol. 1999 Oct;189(2):251-7 [10547583.001]
  • [Cites] J Pathol. 1992 May;167(1):5-8 [1352542.001]
  • (PMID = 20591913.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Other-IDs] NLM/ PMC2989172
  •  go-up   go-down


77. Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A, Mandavilli SR: Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol; 2007 Jun;35(6):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction between malignant mesothelioma and adenocarcinoma is a diagnostic challenge in cytologic specimens of effusion fluids.
  • As for today, no single antibody has demonstrated absolute sensitivity or specificity for Mesothelioma.
  • D2-40 and podoplanin have recently been recognized to stain mesothelial cells.
  • Our aim for this study was to evaluate the utility of these two markers as indicators of mesothelial cells using cell blocks by comparison with two other established mesothelial markers.
  • A total of 40 cell blocks of effusion fluids including cases of epithelioid mesotheliomas, metastatic carcinomas and benign cases with reactive mesothelial cells were selected.
  • D2-40 and podoplanin were positive in 100% of mesothelioma cases in comparison to metastatic adenocarcinoma cases where the positivity was 0%.
  • Since these markers are extremely helpful in differentiating epithelioid mesothelioma from metastatic adenocarcinoma, they shall be a valuable addition to the battery of markers used to differentiate the two entities.
  • [MeSH-major] Antibodies, Neoplasm. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497664.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


78. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
  • Mesothelioma is an asbestos-related tumour.
  • Mesothelioma in the thorax occurs on the pleura and is known as pleural mesothelioma.
  • It is the more common form of mesothelioma, accounting for 70% of cases.
  • It accounts for much of the remaining 30% and is known as peritoneal mesothelioma.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • We update on the current understanding of peritoneal mesothelioma from a clinical perspective in hope that greater clinician awareness will promote best practice management of this condition.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


79. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW: Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax; 2007 Jul;62(7):569-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
  • BACKGROUND: The diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions and metastatic adenocarcinoma.
  • Soluble mesothelin levels in serum have recently been shown to be highly specific and moderately sensitive for mesothelioma.
  • As most patients with mesothelioma present with exudative effusions of either the pleura or the peritoneum, a study was undertaken to determine if levels of mesothelin were raised in these fluids and if the increased levels could help to distinguish mesothelioma from other causes of exudative effusion.
  • METHODS: Pleural fluid was collected from 192 patients who presented to respiratory clinics (52 with malignant mesothelioma, 56 with non-mesotheliomatous malignancies and 84 with effusions of non-neoplastic origin).
  • Peritoneal fluid was collected from 42 patients (7 with mesothelioma, 14 with non-mesotheliomatous malignancies and 21 with benign effusions).
  • RESULTS: Significantly higher levels of mesothelin were found in effusions of patients with mesothelioma; with a specificity of 98%, the assay had a sensitivity of 67% comparing patients with mesothelioma and those with effusions of non-neoplastic origin.
  • In 7 out of 10 cases mesothelin levels were raised in the effusion collected 3 weeks to 10 months before the diagnosis of mesothelioma was made; in 4 out of 8 of these, mesothelin levels were increased in the effusion but not in the serum.
  • CONCLUSIONS: Measurement of mesothelin concentrations in the pleural and/or peritoneal effusion of patients may aid in the differential diagnosis of mesothelioma in patients presenting with effusions.
  • [MeSH-major] Membrane Glycoproteins / metabolism. Mesothelioma / diagnosis. Pleura / chemistry
  • [MeSH-minor] GPI-Linked Proteins. Humans. Pleural Effusion, Malignant / metabolism. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):172-4 [17409849.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):405-10 [11018693.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Chest. 2001 Apr;119(4):1138-42 [11296181.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] Lung. 1994;172(3):183-4 [8201832.001]
  • [Cites] Nephron. 1999;81(4):373-80 [10357643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Chest. 2004 Dec;126(6):1721-2 [15596661.001]
  • [Cites] Chest. 2004 Dec;126(6):1757-63 [15596670.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):357-62 [16012715.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20 [16702385.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1751 [16985043.001]
  • [CommentIn] Thorax. 2007 Jul;62(7):561-2 [17600291.001]
  • [CommentIn] Thorax. 2008 Jan;63(1):87-8; author reply 87 [18156575.001]
  • (PMID = 17356060.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ PMC2117248
  •  go-up   go-down


80. King J, Thatcher N, Pickering C, Hasleton P: Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology; 2006 Dec;49(6):561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
  • AIMS: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease.
  • A high MCM2 labelling index also differentiated between benign and malignant pleural disease.
  • The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunohistochemistry / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Silver Staining
  • [MeSH-minor] Antigens, Nuclear. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Nuclear Proteins. Nucleolus Organizer Region / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163840.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  • [Number-of-references] 33
  •  go-up   go-down


81. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
  • Differentiating cells of mesothelial origin from adenocarcinoma (ACA) based on morphology alone can be a diagnostic challenge, especially in cytological specimens.
  • Malignant mesothelioma (MM) is characterized by accumulation of abundant intracellular hyaluronic acid (HA), a feature that is not reported in ACA.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • In MM and reactive mesothelial cells, CD44S stained cell membranes diffusely with highlights on the villous surfaces and in ACA it was focal and confined to cell membranes.
  • Immunostaining with HA is a reliable marker that can distinguish between cells of mesothelial origin (reactive mesothelial cells and MM) and ACA.
  • The CD44S staining pattern of cells of mesothelial origin is of diagnostic significance.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


82. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC: Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med; 2009 Sep 01;180(5):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
  • RATIONALE: Serum mesothelin is a new biomarker for the diagnosis of mesothelioma.
  • Patients with mesothelioma commonly present with pleural effusions.
  • To define the clinical utility of mesothelin quantification in pleural fluid, we assessed its additional value over pleural fluid cytology and its short-term reproducibility and reliability after pleural inflammatory processes, including pleurodesis.
  • OBJECTIVES: To assess the diagnostic role of pleural fluid mesothelin and the effect of common clinical factors that may influence measurement accuracy.
  • METHODS: Mesothelin was quantified in 424 pleural fluid and 64 serum samples by ELISA.
  • Fluid was collected prospectively from 167 patients who presented with pleural effusions for investigation.
  • Serial pleural fluid samples were obtained from patients (n = 33) requiring repeated drainage.
  • MEASUREMENTS AND MAIN RESULTS: Pleural fluid mesothelin concentrations were significantly higher in patients with mesothelioma (n = 24) relative to those with metastatic carcinomas (n = 67) and benign effusions (n = 75): median (interquartile range, 25th-75th percentile) = 40.3 (18.3-68.1) versus 6.1 (1.5-13.2) versus 3.7 (0.0-12.4) nM, respectively, P < 0.0001.
  • Mesothelin measurement was superior to cytological examination in the diagnosis and exclusion of mesothelioma (sensitivity, 71 vs. 35%; specificity, 89 vs. 100%; negative predictive value, 95 vs. 82%, respectively).
  • In patients with "suspicious" cytology, pleural fluid mesothelin was 100% specific for mesothelioma, and in cytology-negative effusions (n = 105) offered a negative predictive value of 94%.
  • Intraindividual reproducibility of pleural fluid mesothelin was excellent: mean (+/-SD) variation, -0.15 (+/-8.41) nM in samples collected within 7 days from patients with mesothelioma.
  • CONCLUSIONS: Pleural fluid mesothelin provides additional diagnostic value relative to cytological examination.
  • Mesothelin measurements are reproducible and not affected by inflammatory pleural processes.
  • [MeSH-major] Membrane Glycoproteins / metabolism. Pleural Effusion / metabolism
  • [MeSH-minor] Aged. Bacterial Infections / complications. Bacterial Infections / metabolism. Female. GPI-Linked Proteins. Humans. Male. Mesothelioma / complications. Mesothelioma / diagnosis. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / therapy. Pleurodesis. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299498.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600475; United Kingdom / Medical Research Council / / MC/ U122888468; United Kingdom / Medical Research Council / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


83. Bishay A, Raoof S, Esan A, Sung A, Wali S, Lee LY, George L, Saleh A, Baumann M: Update on pleural diseases--2007. Ann Thorac Med; 2007 Jul;2(3):128-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on pleural diseases--2007.
  • BACKGROUND: New information is available on pleural diseases.
  • The authors selected articles to make recommendations on diagnostic and treatment aspects of pleural diseases.
  • 5-Amino-laevulinic acid with fluorescent light combined with white light may allow further diagnostic yield in undiagnosed pleural disease.
  • FDG-PET may allow prognostication of patients with pleural tumors.
  • Utilizing ultrasound by trained Emergency Department physicians is a rapid and effective technique to evaluate non-traumatic pleural effusions in symptomatic patients.
  • Serum osteopontin levels may distinguish patients exposed to asbestos with benign disease from those with pleural mesothelioma.
  • Pleural catheter may prove to be an important palliative modality in treating debilitated patients or patients with trapped lung who show symptomatic improvement with drainage; however, at the present time, these catheters cannot be considered a first line treatment option for patients with malignant pleural effusion.
  • One of the studies reviewed showed no significant difference in tract metastasis in patients with malignant mesothelioma undergoing an invasive pleural procedure with or without irradiation to the procedure site.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Feb;69(2):369-75 [10735665.001]
  • [Cites] Thorax. 2002 Dec;57(12):1005-9 [12454292.001]
  • [Cites] Am J Respir Crit Care Med. 2002 May 1;165(9):1240-4 [11991872.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1992-9 [10570423.001]
  • [Cites] Intensive Care Med. 1999 Sep;25(9):955-8 [10501751.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1682-7 [10556140.001]
  • [Cites] Am J Emerg Med. 2006 Nov;24(7):782-6 [17098097.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8 [17000285.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1535-9 [17482984.001]
  • [Cites] Chest. 2006 Jun;129(6):1577-83 [16778278.001]
  • [Cites] Chest. 2006 Mar;129(3):783-90 [16537882.001]
  • [Cites] Chest. 2006 Mar;129(3):718-24 [16537873.001]
  • [Cites] Chest. 2006 Feb;129(2):362-8 [16478853.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1617-8 [16221786.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Chest. 2005 Aug;128(2):684-9 [16100154.001]
  • [Cites] N Engl J Med. 2005 Mar 3;352(9):865-74 [15745977.001]
  • [Cites] Respiration. 2004 Nov-Dec;71(6):559-66 [15627865.001]
  • [Cites] Photochem Photobiol. 1999 May;69(5):605-10 [10333768.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] Chest. 1997 Aug;112(2):430-4 [9266880.001]
  • [Cites] Thorax. 1997 May;52(5):416-21 [9176531.001]
  • [Cites] Ann Emerg Med. 1997 Mar;29(3):312-5; discussion 315-6 [9055768.001]
  • [Cites] Chest. 1996 Jul;110(1):102-6 [8681611.001]
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Chest. 1995 Aug;108(2):335-9 [7634863.001]
  • [Cites] Chest. 1994 Aug;106(2):342-6 [7774299.001]
  • [Cites] Ann Intern Med. 1994 Jan 1;120(1):56-64 [8250457.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Apr;105(4):743-7; discussion 747-8 [7682268.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Clin Chest Med. 1985 Jun;6(2):237-53 [3161683.001]
  • [Cites] Chest. 1990 Feb;97(2):333-7 [2137075.001]
  • [Cites] Am J Med. 1980 Oct;69(4):507-12 [7424940.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 15;170(4):377-82 [15142871.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] Ann Surg. 2002 Feb;235(2):252-60 [11807366.001]
  • [Cites] Int J Clin Pract. 2001 Dec;55(10):658-60 [11777287.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Respirology. 2001 Sep;6(3):181-5 [11555375.001]
  • [Cites] Chest. 2001 Jun;119(6):1641-6 [11399685.001]
  • [Cites] Chest. 2001 May;119(5):1516-20 [11348962.001]
  • [Cites] Chest. 2001 Feb;119(2):590-602 [11171742.001]
  • [Cites] Respir Med. 2004 Jul;98(7):579-90 [15250222.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):9-10 [15199394.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3474-8 [15161704.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):361-5 [15099946.001]
  • [Cites] Med Sci Monit. 2003 Jun;9(6):PI54-9 [12824959.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii18-28 [12728147.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii39-52 [12728149.001]
  • [Cites] Clin J Oncol Nurs. 2003 Jan-Feb;7(1):35-8 [12629932.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2002 Oct;40(10):773-5 [12487883.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):64-70 [12468344.001]
  • [Cites] Chest. 2000 Oct;118(4):1158-71 [11035692.001]
  • (PMID = 19727362.001).
  • [ISSN] 1817-1737
  • [Journal-full-title] Annals of thoracic medicine
  • [ISO-abbreviation] Ann Thorac Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2732091
  • [Keywords] NOTNLM ; Pleural / effusions / empyema / mesothelioma / pleurodesis / pneumothorax / thoracoscopy / ultrasound
  •  go-up   go-down


84. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A: 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int; 2010 May;60(5):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
  • Previous studies showed that this alteration might be useful for differentiating benign from malignant mesothelial tumors in cytology and surgical specimens.
  • The purpose of this study is to evaluate the diagnostic utility of 9p21 homozygous deletion assessed by FISH in mesothelial neoplasm and hyperplasia of Japanese patients using paraffin-embedded tissue.
  • In contrast, no cases of adenomatoid tumor, benign mesothelial multicystic tumor, reactive mesothelial hyperplasia or pleuritis showed 9p21 deletion (P < 0.005).
  • 9p21 homozygous deletion correlated well with p16 protein expression in the tumor cells.
  • Our study suggests that 9p21 homozygous deletion assessed by FISH on paraffin-embedded tissue may be very useful for differentiating MM from reactive mesothelial proliferation.
  • [MeSH-major] Chromosomes, Human, Pair 9. Genes, p16. Heart Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Epithelium / pathology. Female. Gene Deletion. Gene Dosage. Humans. Pericardium / metabolism. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518890.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


85. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med; 2009 Aug;133(8):1317-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
  • CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose.
  • OBJECTIVE: To develop practical guidelines for the pathologic diagnosis of MM.
  • DATA SOURCES: A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006).
  • CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM.
  • Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory.
  • The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653732.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


86. Meirelles GS, Kavakama JI, Jasinowodolinski D, Nery LE, Terra-Filho M, Rodrigues RT, Neder JA, Bagatin E, D'ippolito G: [Asbestos-related pleuropulmonary diseases: pictorial essay]. Rev Port Pneumol; 2005 Sep-Oct;11(5):477-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleural and pulmonary asbestos-related diseases range from benign conditions, like pleural effusion and pleural plaques, to some neoplasias, such as lung cancer and malignant mesothelioma.
  • Pleural effusion is the earliest finding after asbestos exposure, but the imaging findings are not specific.
  • Diffuse pleural thickening involves the visceral pleura and pleural plaques are considered to be hallmarks of exposure.
  • Rounded atelectasis is a peripheral lung collapse in these individuals, generally related to pleural disease.
  • Some neoplasias, like lung carcinoma and pleural mesothelioma, are more prevalent in asbestos-exposed subjects.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / radiography. Pleural Diseases / etiology. Pleural Diseases / radiography

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288346.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Portugal
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 38
  •  go-up   go-down


87. Santos RS, Haddad R, Lima CE, Liu YL, Misztal M, Ferreira T, Boasquevisque CH, Luketich JD, Landreneau RJ: Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura. Clin Lung Cancer; 2005 Nov;7(3):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.
  • BACKGROUND: Localized fibrous tumors of the pleura (LFTPs) are uncommon thoracic neoplasms with variable malignant potential that were previously classified as benign presentation of mesothelioma.
  • The malignant potential of the tumor was estimated through histologic assessment of the degree of cellularity, mitotic activity, and nuclear pleomorphism.
  • Ipsilateral pleural recurrence remote to the original tumor site occurred in 6 of these patients with malignant microscopic characteristics at a mean of 9 months after resection.
  • There have been no recurrences among the other 27 patients with benign histologic features, and 31 patients remain alive at a median follow-up of 34.5 months.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Fibrous Tissue / surgery. Pleura / surgery. Pleural Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354315.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Podobnik J, Kocijancic I, Kovac V, Sersa I: 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results. Radiol Oncol; 2010 Jun;44(2):92-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five had a benign form of the disease and 10 had malignant pleural mesothelioma (MPM).
  • From the patients with a benign form of the disease their last CT examination in digital form was acquired and patients with MPM were scheduled for CT examination with contrast media.
  • RESULTS: Compared to muscles pleural plaques appeared hypo-intense to iso-intense on T1 weighted images (in 100%) and also hypo-intense on T2 fs-weighted images (in 100%).
  • CONCLUSIONS: These preliminary results pointed out that MRI was equal or even better compared with CT examination for detecting possible malignant potential of pleural changes in the asbestos-related pleural disease, using signal intensity measurements of T2 fs-weighted images.
  • This finding turned us to propose 3T MRI imaging technique as a non-ionizing imaging method for the follow-up of patients with the isolated pleural form of the asbestos-related disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):963-8 [8610582.001]
  • [Cites] Eur Respir J. 1998 Jan;11(1):194-7 [9543293.001]
  • [Cites] Eur J Radiol. 2000 Jun;34(3):196-207 [10927161.001]
  • [Cites] Acta Radiol. 2001 Sep;42(5):502-7 [11552888.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Invest Radiol. 2004 Sep;39(9):554-64 [15308938.001]
  • [Cites] Eur Radiol. 2005 Feb;15(2):324-8 [15565313.001]
  • [Cites] Radiology. 2008 Feb;246(2):596-604 [18056854.001]
  • [Cites] Invest Radiol. 2007 Jun;42(6):377-83 [17507808.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • (PMID = 22933897.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423685
  • [Keywords] NOTNLM ; 3T, magnetic resonance imaging / asbestos-related thoracic disease / malignant pleural mesothelioma
  •  go-up   go-down


89. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, Kutlu CA: The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg; 2009 Jun;57(4):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
  • BACKGROUND: The aim of the study was to assess the role of F-18 fluoro-2-D-deoxyglucose positron emission tomography ( (18)FDG-PET)/computed tomography (CT) in patients with undiagnosed pleural diseases and to compare the findings with those of invasive diagnostic procedures.
  • METHODS: The study included 83 patients with pleural lesions (63 with pleural effusion; 20 with pleural thickening) on CT scan performed between November 2005 and December 2007.
  • For histopathological diagnosis, video-assisted thoracoscopic surgery was performed in 76 patients and a mini-thoracotomy was performed for the remaining 7 patients.
  • RESULTS: Postoperative histopathological examination revealed malignancy in 44 cases, 25 of which were malignant mesothelioma; the remaining 39 cases were benign.
  • CONCLUSION: Our study suggests that PET-CT may be an effective tool for the differentiation of benign and malignant pleural diseases.
  • [MeSH-major] Pleural Diseases / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Male. Mesothelioma / diagnosis. Mesothelioma / pathology. Middle Aged. Pleural Effusion / diagnosis. Pleural Effusion / pathology. Pleural Neoplasms / diagnosis. Radiopharmaceuticals. Sensitivity and Specificity. Thoracic Surgery, Video-Assisted. Thoracotomy. Tuberculosis, Pleural / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 19670115.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Saad RS, Cho P, Liu YL, Silverman JF: The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol; 2005 Mar;32(3):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
  • Differentiating reactive mesothelial (RM) proliferation from malignant mesothelioma (MM) can be cytologically challenging.
  • Twenty cases of pleural effusion smears of RM and 20 cases of MM with their corresponding cell blocks were retrieved from the hospital computer system.
  • Diagnosis of MM was confirmed by surgical decortication or pneumonectomy with immunostaining studies and/or electron microscopy.
  • [MeSH-major] Mesothelioma / diagnosis. Mucin-1 / metabolism. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Aged. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pleural Effusion / diagnosis. Pleural Effusion / metabolism. Pleural Effusion / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690334.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


91. Scherpereel A, French Speaking Society for Chest Medicine (SPLF) Experts Group: Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med; 2007 Jun;101(6):1265-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
  • Previously considered as a rare tumor, malignant pleural mesothelioma (MPM) has become a very important public health issue.
  • In fact, MPM is a tumor with a poor survival, and its incidence is expected to continue to increase for at least the next 10 years.
  • The diagnosis of MPM may be difficult because of differential diagnosis such as pleural benign disease induced by asbestos exposure or pleural metastasis of adenocarcinoma.
  • Between April 2005 and January 2006, the French Speaking Society for Chest Medicine (SPLF), in collaboration with other French scientific societies, brought together experts on mesothelioma to draw up recommendations in order to provide clinicians with clear, concise, up-to-date guidelines on management of MPM, presented in this report.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17137779.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 11
  •  go-up   go-down


92. Scherpereel A, Lee YC: Biomarkers for mesothelioma. Curr Opin Pulm Med; 2007 Jul;13(4):339-443
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Mesothelioma is an incurable cancer and its global incidence continues to increase.
  • There has been strong interest in the search for a biomarker that would be of value for the diagnosis, prognosis and disease monitoring of mesothelioma.
  • RECENT FINDINGS: To date, global gene profiling studies have failed to find a molecule that reliably captures all subtypes of mesothelioma, and differentiates it from benign pathologies and metastatic carcinomas.
  • SMRP testing is clinically available and provides reasonable diagnostic sensitivity and specificity when applied to serum or pleural fluid.
  • False negatives are common with sarcomatoid mesothelioma.
  • SMRP levels may reflect tumor load and disease progression.
  • The role of SMRP in predicting mesothelioma development in subjects exposed to asbestos has raised interest.
  • Osteopontin lacks specificity as a diagnostic marker for mesothelioma but may have value in disease monitoring.
  • SUMMARY: The proposed markers have insufficient accuracy to replace cytohistology as the gold standard for diagnosis for mesothelioma.
  • Elevated SMRP levels raise suspicion of mesothelioma although negative values do not exclude disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / metabolism. Pleural Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534183.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


93. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H: Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol; 2005 Mar;32(3):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
  • The morphological evaluation of cytological specimens from body cavity fluids presents difficulties in the differential diagnosis between benign reactive mesothelial (RM) cells and adenocarcinoma (AC) or malignant mesothelioma (MM).
  • The aim of our study was to investigate whether a panel of five different antibodies can offer reliable markers in the differential diagnosis of RM, AC, and MM in serous effusions.
  • A total of 134 cytological specimens of serous effusions from 80 ACs, 50 RMs, and 4 MMs, previously stained with Papanicolaou stain, were selected retrospectively from our files and stained with anti-human mesothelial cell (HBME-1), calretinin, epithelial specific antigen (MOC-31), Ber-EP4, and BG8.
  • Statistical significance was found with HBME-1, calretinin, MOC-31, anti-human epithelial antigen (Ber-EP4), and blood group related antigen (BG8) when comparing AC vs. any type of mesothelial proliferation (MM or RM).
  • The sensitivity of HBME-1 and calretinin for mesothelial cells was 98 and 100%, respectively, and the specificity was 71 and 80%, respectively.
  • Both antibodies stained reactive mesothelial as well as MM cells, with calretinin showing a stronger intensity of immunostaining.
  • Our data suggest that immunocytochemical studies performed on Papanicolaou-stained cytological smears with HBME-1, calretinin, MOC-31, Ber-EP4, and BG8 proved to be useful in the differentiation between metastatic AC and mesothelial proliferation.
  • Probably, calretinin is a more preferred marker for mesothelial cells as evidenced by a more intense staining reaction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascitic Fluid / pathology. Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Pericardial Effusion / pathology. Pleural Effusion / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690338.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D: Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med; 2008 Jan;132(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Differentiating reactive effusion, malignant mesothelioma, and metastatic adenocarcinoma in body cavity fluids can be challenging.
  • OBJECTIVE: To evaluate the efficacy of 5 immunohistochemical markers in the differential diagnosis of reactive mesothelial proliferation, malignant mesothelioma, and metastatic adenocarcinoma in body cavity fluids.
  • DESIGN: A total of 72 formalin-fixed, paraffin-embedded cell block specimens from pleural and peritoneal effusions, including 5 mesotheliomas, 48 adenocarcinomas, and 19 benign effusions were stained with antibodies against calretinin, D2-40, XIAP, MOC-31, and WT1.
  • RESULTS: All benign effusions and mesotheliomas demonstrated diffuse membranous staining with D2-40.
  • All mesotheliomas displayed calretinin positivity, whereas only 58% of benign effusions stained focally with calretinin.
  • MOC-31 was positive in all cases of adenocarcinoma, whereas all benign effusions and mesotheliomas were negative.
  • However, background reactive mesothelial cells were positive for calretinin and D2-40.
  • Overall, D2-40 highlighted more mesothelial cells than calretinin.
  • WT1 was positive in 50% of benign effusions, 60% of mesotheliomas, and 27% of adenocarcinomas.
  • XIAP stained most mesotheliomas (80%), some adenocarcinomas (51%), and rare benign effusions (11%).
  • CONCLUSIONS: MOC-31 and D2-40 were very sensitive and specific markers of epithelial and mesothelial cells, respectively.
  • Compared with calretinin, D2-40 was a more sensitive marker of mesothelial cells.
  • [MeSH-major] Adenocarcinoma. Biomarkers, Tumor / analysis. Body Fluids / chemistry. Epithelium / chemistry. Mesothelioma / chemistry. Pleural Effusion, Malignant / chemistry
  • [MeSH-minor] Antibodies, Monoclonal / analysis. Antibodies, Monoclonal, Murine-Derived. Calbindin 2. Cell Proliferation. Diagnosis, Differential. Humans. Hyperplasia / diagnosis. S100 Calcium Binding Protein G / analysis. WT1 Proteins / analysis. X-Linked Inhibitor of Apoptosis Protein / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181669.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / WT1 Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 0 / monoclonal antibody D2-40
  •  go-up   go-down


95. Wheeler YY, Burroughs F, Li QK: Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature. Diagn Cytopathol; 2009 Oct;37(10):748-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature.
  • Well-differentiated papillary mesothelioma (WDPM) is an uncommon subtype of epithelioid mesothelioma.
  • In contrast to malignant epithelioid mesothelioma, WDPM has a low malignant potential and an indolent clinical course.
  • WDPM may be difficult to diagnose and differentiate from benign reactive mesothelial cells and other malignant neoplasm on cytology specimens due to the presence of papillary or tubulopapillary clusters of tumor cells.
  • The cytology of ultrasound-guided fine-needle aspiration (FNA) of the left inguinal hernia and peritoneal masse reveal cellular specimens with numerous individual and tubulopapillary clusters of epithelioid mesothelial cells in a background of scant hyalinized material.
  • Tumor cells show minimal cytological atypia.
  • The differential diagnoses are broad and include reactive mesothelial cells, WDPM, and other malignant neoplasm.
  • It is important to recognize this entity in the differential diagnosis, because the clinical management of WDPM is quite different from that of malignant neoplasm.
  • On the basis of the published data in the literature, it suggests that in male patients, the WDPM occurs predominantly in pleural cavity of older men in their 50s, and about half of the patients have history of asbestos exposure.
  • [MeSH-major] Hernia, Inguinal / pathology. Inguinal Canal / pathology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19373910.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


96. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control; 2006 Oct;13(4):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura.
  • BACKGROUND: The solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura.
  • The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura.
  • METHODS: In just over half of these cases, the neoplasm presents as an asymptomatic mass, is often quite large, and is benign in 78% to 88% of patients.
  • The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
  • RESULTS: Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor.
  • The pedunculated tumors attached to the visceral pleura can be effectively treated with a wedge resection of lung.
  • CONCLUSIONS: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision.
  • The majority of patients with recurrent disease die of the tumor within 2 years.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Neoadjuvant Therapy. Thoracic Surgical Procedures. Tomography, X-Ray Computed. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075563.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


97. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem; 2009 Jul;42(10-11):1046-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
  • We assessed comparatively the diagnostic value of two potential malignant pleural mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin.
  • MATERIALS AND METHOD: We measured serum and pleural fluid values of mesothelin and hyaluronic acid in 76 patients with MPM, 33 patients with pleural metastases of carcinomas (Mets group) and 27 patients with benign pleural effusion related to asbestos exposure (BPLAE).
  • In pleural fluid, both markers had similar diagnostic values.
  • [MeSH-major] Hyaluronic Acid / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis
  • [MeSH-minor] Aged. Female. GPI-Linked Proteins. Humans. Male. Pleural Effusion / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302997.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


98. Factor RE, Dal Cin P, Fletcher JA, Cibas ES: Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma. Cancer; 2009 Aug 25;117(4):247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma.
  • Although the chromosome regions affected by these aberration(s) may vary from 1 tumor to another, certain regions are commonly disrupted.
  • These aberrations are absent in benign mesothelial cells, and therefore their presence can be used to confirm a diagnosis of MM.
  • METHODS: A retrospective analysis of 48 pleural or peritoneal fluids from patients with histologically confirmed MM was performed.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Mesothelioma / genetics


99. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and functional imaging of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor that arises from the pleura and frequently extends to adjacent structures.
  • Major findings include nodular pleural thickening, unilateral pleural effusion, and tumor invasion of adjacent structures.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion MRI is the most promising technique for the assessment of the tumor microvasculature.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • An initial report on PET/CT imaging of MPM has shown increased accuracy of overall staging, improving the assessment of tumor resectability.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods


100. Németh T, Furák J, Wolfárd A, Géczi T, Tiszlavicz L, Lázár G: [Surgical treatment of primary pleural tumours in our department]. Magy Seb; 2010 Apr;63(2):67-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of primary pleural tumours in our department].
  • AIM: The authors analyzed the results and outcome of surgical treatment of primary pleural tumors in patients treated in the last 11 years.
  • METHODS: 31 operations were performed for primary pleural tumors in 25 patients (17 males, 8 females).
  • The tumors were classified into the following groups: benign local fibrous tumors (benign LFTP; n = 15), recurrent malignant fibrous tumors (recurrent malignant LFTP; n = 2) and malignant mesotheliomas (MPM; n = 12).
  • Complete resections of benign LFTPs were performed, with additional resection of the chest wall and lobectomy in two cases.
  • In four cases, after the biopsy, two pleurectomies and decortications (P/D) and two pleuropneumonectomies (PPN)/extra-pleural pneumonectomies (EPP) were carried out.
  • [MeSH-major] Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Biopsy. Carcinoma / surgery. Female. Humans. Hungary. Male. Mesothelioma / surgery. Middle Aged. Neoplasm Staging. Pleurodesis. Pneumonectomy. Retrospective Studies. Sarcoma / surgery. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20400397.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down






Advertisement